Stephen G. Holtzman Travel Award for Preclinical Investigators

**Drew Townsend, Ph.D**
Virginia Commonwealth University

Dr. Drew Townsend’s longstanding research interest is to better understand the determinants and mechanisms of drug-taking behavior, with the goal of developing improved treatment strategies for substance use disorders. Drew’s interest in substance-abuse research was cemented during an undergraduate internship with Dr. Kevin Freeman at the University of Mississippi Medical Center in 2011. Drew was fortunate enough to continue this research with Dr. Freeman through the completion of his PhD in neuroscience in 2017, focusing on the use of opioid self-administration procedures to evaluate strategies to diminish the abuse liability of opioid analgesics. Drew is currently a postdoctoral fellow within the laboratory of Dr. Matt Banks at Virginia Commonwealth University. Drew’s postdoctoral research focuses on the evaluation of opioid-targeted vaccines, an endeavor that is supported by an F32 fellowship from NIH/NIDA. A primary achievement during this period has been the successful translation of an opioid-versus-food choice procedure from non-human primates to rats. Drew hopes to leverage this choice procedure to investigate mechanisms underlying the role of opioid withdrawal on the choice to self-administer fentanyl over a food alternative. Drew will share emerging findings related to a fentanyl-targeted vaccine during CPDD 2020.

**CPDD International Award**

**Joao Mauricio Castaldelli-Maia, M.D., Ph.D**
University of Sao Paulo Medical School

Dr. Castaldelli-Maia in an Auxiliary Professor at the Department of Neuroscience, ABC Health University Center, and a Postgraduate Supervisor at the Department of Psychiatry, Medical School, University of Sao Paulo, Brazil. An essential part of his work was devoted to implementing smoking cessation treatment for individuals with mental disorders using pharmacological agents associated with group therapy in Brazil, Portugal, and France. In addition, he led the first studies to investigate the dimensionality and measurement bias of the DSM-5 and ICD-11 diagnosis for substance
use disorders in a population-based sample of a developing country, receiving an Honorable Mention in the Health Science & Technology Prize of the Brazilian Ministries of Health, and Science & Technology for these studies. This year he has been awarded as a NIDA INVEST Drug Abuse Research Fellow. He will join the Department of Epidemiology of Columbia Mailman School of Public Health, to investigate determinants of fatal opioid polydrug overdoses over the last ten years, linking five different databases. He will use a mixed ecological design, mixing multigroup ecological analyses and time trends, as well as a type of machine learning to identify clusters at the U.S. county level.

**Matiwos Soboka Daba, M.Sc, Assistant Professor**  
*Jimma University*

Mr. Matiwos Soboka is a mental health specialist with 7 years of experience in different positions and institutions. He has a master’s degree in integrated clinical and community mental health from Jimma University and BSc in nursing from Haramaya University. Then he has worked as head of a health center and vice head of a district health office for two years. Then he joined Jimma University as a lecturer and promoted to an assistant professor after three years of service. In Jimma University he has been serving as coordinator of mhGAP training and master program at the department of psychiatry. On top of teaching and conducting researches, he is currently serving as an ethical officer at Jimma University Institute of Health.

**Oyapero Afolabi, BDS, MPH., FMCDS**  
*Lagos State University College of Medicine*

Dr Oyapero Afolabi is a Specialist public health professional and University lecturer with over 15 years’ experience in clinical, public health and academic contexts with proficiency in appropriate technology in resource constrained settings and exposure to cutting edge technology in developed country contexts.

Dr Oyapero has employment, research and collaboration experience with Ministries of health, Universities, Teaching Hospitals, Federal government agencies and with international bodies (SASA; ISPTID; ECToH, SRNT, IFIC; IADR; International Aids Society; Society for Prevention Research; Global Bridges; WHO:PAHO), in nations (Nigeria/Japan/Germany/Canada/ United State of America),and establishments (Global bridges-Mayo Clinic/ The John Hopkins Bloomberg school of Public Health/ Ontario Tobacco Research unit/ Society for Research on Nicotine and Tobacco/ University of Iowa.)

His recent research focus includes tobacco control, exposure of vulnerable children to Tobacco, genetics and epidemiology of oral diseases and quality of life outcomes. He is a Mayo Clinic certified Tobacco cessation specialist and he runs a drug addiction clinic where he also conducts screening for oral cancer.

He is skilled in epidemiology, biostatistics, advocacy, data analysis and dissemination of scientific information using Epi info, SPSS, Stata. He has expertise in policy drafting, public health program planning, implementation of programs, surveillance and program evaluation.
Vitor Soares Tardelli, M.D., M.S.
Universidade Federal de Sao Paulo

Vitor is an addiction psychiatrist and currently a PhD candidate (expected to finish by May/2021). I am interested in clinical trials, systematic reviews, and meta-analyses in the field of treatment of stimulants use disorders. Moreover, I develop epidemiological research with large datasets about the non-medical use of prescription drugs and inhalant use in vulnerable populations. I am also involved in a project that aims to study sociodemographic, drug-related, and geospatial characteristics of individuals deceased by intentional or unintentional overdose in Sao Paulo, Brazil.

Suzaily Wahab, M.D., DR(PSYCH)
University Kebangsaan Malaysia Medical Centre

Dr. Suzaily Wahab is an Associate Professor and Consultant Psychiatrist in the faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre (UKMMC). She also serves as a council member of the Addiction Medicine Association of Malaysia (AMAM) from 2016 until current. Dr. Suzaily’s primary research interest is in the area of mental health, addiction and high risk behaviours, which includes maltreatment and cyber health threats, with a special focus on youth, women, and families. She is also an avid speaker in several national/ international conferences, seminars, and media platforms, to promote and educate the community on mental health issues. Dr. Suzaily has been actively involved in several international collaborative research projects and had received national/ international grants for her research projects in addiction and mental health. Her latest addiction research project focuses on the prevention and intervention of methamphetamine use in youth. She has also authored/ co-authored several books/book chapters focusing on mental health issues, such as adolescent addiction, cyber bullying, and schizophrenia. Her research writings were also shared and disseminated through peer reviewed journals and Malaysian media outlets.

CPDD Primm-Singleton Minority Travel Award

Naomi Dambreville, Ph.D
The Graduate Center & The City College of New York, CUNY

Dr. Naomi Dambreville’s (she/her) research interests lies in assessing the interpersonal dysfunctions associated with risky behaviors, such as substance use, using translational approaches that support novel clinical interventions. She is also interested in racial/ethnic minority disparities and has co-authored multiple peer-reviewed publications. As a Postdoctoral Fellow, Dr. Dambreville currently serves as a primary clinician for adolescents/young adults with histories of trauma and/or substance use, as well as their families. Dr. Dambreville obtained her PhD in 2019 from the Clinical Psychology Program at City College (CCNY) and The Graduate Center, CUNY. Dr. Dambreville is a recipient of the Barmack Award for Best PhD thesis, Psychology Department, CCNY and an alumna Scholar of the Translational Research Training in Addictions for Racial/Ethnic Minorities at CCNY and Columbia University Medical Center (TRACC) program.
Fernando B. de Moura, Ph.D.
Harvard Medical School/McLean Hospital

Fernando Barreto de Moura, Ph.D. is a junior faculty member in the Behavioral Neuroimaging Laboratory at Harvard Medical School/McLean Hospital. Dr. Moura’s studies integrate cutting-edge neuroimaging techniques concurrently with preclinical models to elucidate behavioral and neurobiological mechanisms associated with substance use disorders and other psychiatric conditions. Trained classically as a behavioral pharmacologist, Dr. Moura is also interested in using receptor theory and behavioral economics to better model, characterize, and study substance use disorders preclinically.

Dr. Moura received his Ph.D. in pharmacology from the University of Texas Health Science Center in 2017, and he joined the Behavioral Biology Program at McLean Hospital in the same year as a postdoctoral research fellow. During his postdoctoral tenure, Dr. Moura continued to grow his expertise in behavioral pharmacology, as well as learn about advanced neuroimaging techniques under the mentorship of Drs. Stephen Kohut and Jack Bergman. Following his postdoctoral studies, Dr. Moura continues to work with Dr. Kohut in the Behavioral Neuroimaging Laboratory.

Mariely Hernandez, M.A.
The City University of New York

Mariely Hernandez is a Doctoral Candidate in Clinical Psychology at The City College of New York/CUNY Graduate Center. She is broadly interested in developmental psychopathology, risk factors for mental illness, emotion regulation, and cognitive function in clinical populations. Specifically, her most recent research has focused on exploring whether college students with childhood ADHD symptoms experience more negative outcomes following alcohol use in adulthood than their typically developing peers with comparable rates of alcohol use. Other projects center around ADHD as a risk factor for developing substance and alcohol use disorders, as well as exploring baseline predictors of retention in a clinical trial for cannabis dependence. Previous research interests have focused on risk factors and early predictors of bipolar disorder, and broad child psychopathology in at-risk populations. Prior to joining Dr. Sarah O’Neill’s Attention & Neuropsychological Development lab, Mariely researched pharmacological interventions for pediatric bipolar disorder at Massachusetts General Hospital, and parental depression and child psychopathology at the New York State Psychiatric Institute. She earned a BA in Neuroscience from Columbia University and an MA in Psychology from Teachers College.

Danielle S. Jackson M.D., M.P.H
McGaw Medical Center at Northwestern University

Dr. Jackson received her MD from Howard University College of Medicine in 2013. Her mission as a psychiatry/behavioral health physician is influenced dually by lived experience as a Black American first-generation college student from North Philadelphia as much patient care experiences early in training as a surgical resident. Her area of study is the intersection of social justice and structural racism that contribute to health inequities in Black Americans with mental health and/or substance use disorders. In 2019 she was selected as a Resident Scholar in the inaugural cohort of the Recognizing and Eliminating Disparities in Addiction through Culturally informed Healthcare (REACH) Program. As a scholar, she developed expertise in health disparities and structural competency issues that serve as barriers to treatment in underserved communities. She cultivated early leadership skills: as elected American
Psychiatric Association- Black Caucus, ECP representative, and AAAP ECP Co-Chair. In her spare time, she utilizes social media as a platform for advocacy and education. She is currently working to develop multidisciplinary structural racism and health equity education for addiction treatment providers. Recently she was awarded the SAMHSA Minority Substance Abuse Fellowship for 2020-2021. She hopes to develop new patient education in addiction treatment during her fellowship.

Luisa Kcomt, Ph.D, M.SW, B.S.W
University of Michigan

Dr. Luisa Kcomt is a post-doctoral research fellow at the University of Michigan’s Center for the Study of Drugs, Alcohol, Smoking and Health. She has served as a social worker for 25 years, in both clinical and leadership capacities. As she embarks on a new career in research, she strives to integrate the social work profession’s value of social justice into her research agenda. With the belief that research can be used as an advocacy tool to serve marginalized populations, her research interests include substance use and health disparities among sexual and gender minority populations. Her clinical experience grounds her current work as a researcher by underscoring the clinical relevance of her research activities. Dr. Kcomt holds an active license as a Licensed Master of Social Work in the state of Michigan, where she currently resides with her son.

Natasha Ludwig-Barron, Ph.D (c), M.P.H
University of Washington

Natasha Ludwig-Barron, Ph.D(c), MPH, is a doctoral candidate in Epidemiology at the University of Washington. Her research interests fall within intersection of substance use, HIV/AIDS, and gender inequity, with the goal of improving the health and wellbeing of marginalized communities both domestically and globally. She is a NIH NIDA Diversity Supplement recipient, which supports her training and research in Nairobi and coastal Kenya. Her dissertation incorporates a mixed methods design in order to better understand environmental risk factors that impact HIV and HCV care among HIV-positive, persons whom injection drug (PWID). She earned an MPH at Emory University, followed by a fellowship through the Hispanic-Serving Health Professions Schools to conducted HIV and substance use research along the U.S.-Mexico Border. Later Ms. Ludwig-Barron served as an Epidemiologist/Study Director with the Los Angeles County Department of Public Health, where she evaluated county-wide programs in the HIV & STI Research and Innovation Unit. Her goals are to increase evidence-based, programs and services for communities with substance use disorders and associated co-morbidities, while encouraging young Latinx/Chicanx, first generation college students to pursue higher education.

Maylen Perez Diaz, Ph.D
University of California Los Angeles

Dr. Perez Diaz immigrated to the U.S. from Cuba as a child and has dedicated her career in research to studying the neural mechanisms underlying addiction, with specific focus on behavioral pharmacology, neuroendocrinology, and neuroimaging. She received her B.S. in Biology from UCLA in 2011 and went on to earn her Ph.D. in Neuroscience from Emory University under the mentorship of Drs. Leonard Howell and Mark Wilson in 2017. She is currently working on her postdoctoral training with Dr. Eddythe London at UCLA, studying the neural mechanisms underlying withdrawal-related states in cigarette smokers. Dr. Perez Diaz plans to continue
pursuing a career in academic research, seeking out new avenues for drug addiction therapies and mentoring young scientists in training. As a Latina woman in science, she hopes to encourage and mentor other young women of color in order to diversity and move the field forward.

**Simon Sandh, M.P.H**  
*New York University College of Global Public Health*

Simon Sandh is a doctoral candidate studying epidemiology at the New York University School of Global Public Health researching topics such as substance use, HIV, sexual health, and sexual minorities. He received his Master of Public Health with a concentration in maternal, child, reproductive, and sexual health at the CUNY School of Public Health. While at CUNY, he focused his research on sexual health of men who have sex with men and health technology. His interest in substance use arose through his work at the New York State Psychiatric Institute where he conducted preliminary eligibility screenings for several opioid studies and collected participant observation data for cannabis studies. His current research projects include substance use among construction workers as well as sexual health of men who have sex with men and transgender women in the Philippines. As he progresses in his research, he hopes to work towards joining the gap between his interests in working with sexual minorities, particularly in the realm of HIV, with his interest in substance use research.

**Trey B. Warren, M.P.H Candidate**  
*University of Florida*

Trey B. Warren is a graduate research trainee in the Study of Teen Opioid Misuse and Prevention Laboratory at the University of Florida, led by Dr. Linda B. Cottler. He aims to become a tenured professor and independent investigator in the epidemiology of varying misused substances (i.e. opioid misuse epidemiology), and racial and ethnic health disparities among pediatric populations. His primary research focuses on the psychological and social determinants of pediatric health disparities, with an emphasis on the quantitative analysis of risk factors associated with opioid misuse among justice-involved children.

**Sitara Weerakoon, B.A., M.P.H**  
*UTHealth SPH*

Sitara Weerakoon, MPH is a PhD student in Epidemiology and Biostatistics at the University of Texas Health Science Center School of Public Health in Dallas, TX. She studies maternal prenatal substance abuse and adolescent cardiovascular and anthropometric outcomes. Her research interests also include exploration of racial and ethnic disparities in child and teen health and applying statistical methods for epidemiological study questions. Sitara is a member of the Delta Omega Honorary Society in Public Health -- Alpha Iota chapter. Sitara graduated from Austin College in Sherman, TX with a Bachelor of Arts degree where she double majored in Public Health and French. She is a Sri Lankan American and a first-generation doctoral student. Her hobbies include traveling, reading, and playing with her mini schnoodle, Rigby.


F.O.R.C.E. Junior Investigator Travel Award

Kathryn Hawk, M.D., M.H.S
Yale University Department of Emergency Medicine

Dr. Hawk is an Assistant Professor in the Department of Emergency Medicine and an attending physician in the Yale New Haven Hospital Emergency Department. She is a NIDA K12 Drug use, Addiction and HIV Research (DAHRS) Scholar, and is board certified in emergency and addiction medicine. She completed her residency training, a year of service as chief resident, and a research fellowship in the Yale University Department of Emergency Medicine. Her research primarily focuses on implementation of programs initiating buprenorphine in the ED and opioid overdose prevention. She is an investigator on several NIDA CTN multi-site studies (CTN 0069, 00790, 0079-A1, CTN 0099) focused on the implementation of ED-initiated buprenorphine in academic, community and rural EDs, and on the impact of engagement in formal addiction treatment in those receiving and injectable versus sublingual buprenorphine in the ED. In addition, she has been engaged in multiple projects focused on reducing opioid associated mortality through data linkages, ED naloxone distribution, ED patient experience and reported outcomes, and dissemination of evidence-based best practices for emergency care of patients with addiction.

Ashly E Jordan, Ph.D, M.P.H
New York University

Dr. Jordan's research addresses the interface of substance use, infectious disease risk, and clinical- and population-level surveillance, screening, interventions, and prevention. Drawing on a multi-level understanding of illness and health, she employs both advanced quantitative and qualitative methods to better understand factors and policies which contribute to risk and which could be modified to improve individual and population health through screening, testing, treatment, and prevention. Dr. Jordan's current research examines the epidemics of opioid misuse, overdose, HIV and hepatitis C virus (HCV). epidemics can be best understood as a syndemic, that is, a set of inter-related and overlapping epidemics occurring in specific geospatial and socio-economic contexts and which act synergistically to exacerbate risk.

Noa Krawczyk, PhD
NYU School of Medicine

Noa Krawczyk is an Assistant Professor in the Department of Population Health at NYU Grossman School of Medicine and a member of the Center for Opioid Epidemiology and Policy. She completed her PhD in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health, where she studied substance use epidemiology, and previously worked as a Fulbright research scholar to study treatment and health services among cocaine users in Brazil. Her research focuses on studying ways to address barriers to evidence-based treatment for opioid use disorders and improving quality and effectiveness of care, especially among vulnerable groups such as persons with criminal justice involvement. Her work centers on bridging research and practice by collaborating with public health and government agencies and advancing science that can help inform evidence-based policies and practices that reduce harm and promote long-term recovery.
Olufemi Ajumobi, M.D, M.P.H
University of Nevada Reno

Olufemi is a doctoral student in the Public Health PhD program (Social Behavioral Health Track) at the University of Nevada, Reno. He holds a Bachelors degree in Medicine and Surgery (equivalent to MD) from the University of Ibadan – Nigeria; and a Master of Public Health (Field Epidemiology) from Ahmadu Bello University Zaria – Nigeria, a program modeled after the U.S Epidemic Intelligence Service. His PhD research interests include substance use mitigation and efficacy and implementation of peer recovery support.

Rachel Altshuler, Ph.D.
University of Maryland - College Park

Rachel Altshuler received her Ph.D. from the University of Michigan in 2019. During her graduate studies, Rachel received training in neuropharmacology and behavioral pharmacology from the Department of Pharmacology in the labs of Dr. Emily Jutkiewicz and Dr. Margaret Gnegy. Rachel's research focused on the effects of protein kinase C inhibition on amphetamine-mediated behaviors in rats. After leaving Michigan, Rachel began her postdoctoral research in the lab of Dr. Xuan Li in the Department of Psychology at the University of Maryland. Rachel's postdoctoral research focuses on the neurobiology of drug relapse.

Erin M. Anderson Goodell, Ph.D Sc.M
Johns Hopkins Bloomberg School of Public Health

Erin Anderson Goodell is a second-year Postdoctoral Fellow in the Department of Mental Health at Johns Hopkins Bloomberg School of Public Health (JHSPH). She holds a PhD in mental health also from JHSPH and a Masters degree in epidemiology from the Harvard T.H. Chan School of Public Health. Her primary research expertise focuses on effects of interpersonal and environmental factors on illicit drug and alcohol use among military personnel. She also has emerging expertise in research using smartphone technology and novel methods such as ecological momentary assessment to measure and intervene on patterns of substance use.

Anahita Bassir Nia, M.D.
Yale University School of Medicine

Anahita Bassir Nia, MD, is an Addiction Psychiatrist by training and an Assistant Professor of Psychiatry at Yale School of Medicine. She has recently received her career development award (K12) to study the endocannabinoid system in opioid use disorder and is funded to study the endocannabinoid system in post-traumatic stress disorder (PTSD) from National Center for PTSD (NCPTS). Her main research interests are in conducting translational research to understand the neurobiology of addictive disorders, particularly in relation to the role of long-lasting effects of chronic stress and trauma on the psychopathology of substance use disorders.
Gayatri Bhatia, M.D.
All India Institute of Medical Sciences

Dr. Gayatri Bhatia completed her MD (Psychiatry) in 2018 and is currently pursuing DM (3 years’ super-specialization) in Addiction Psychiatry from the National Drug Dependence Treatment Centre, All India Institute of Medical Sciences (AIIMS), New Delhi, India. She has a special interest in understanding and management of mental health issues of women, adolescents and young adults, especially students, with active involvement in Institutional Student Guidance Cell and Resident Doctors’ Association at AIIMS. Her research work includes multiple research projects and publications in the areas of adolescent mental health and addiction psychiatry, behavioral addictions and family interventions in substance use disorders. She takes keen interest in teaching and exchange of ideas, organizing interactive sessions for students and resident doctors, actively participating in open forums, winning many laurels in debates, creative writing and regional music.

Kathryn Biernacki, Ph.D
Department of Psychiatry, UBHC, and Brain Health Institute, Rutgers University – New Brunswick

Dr Biernacki is a postdoctoral research associate at Rutgers University. She completed her PhD in Psychology in Australia, before moving to Rutgers University to continue her work with opioid-using populations. Her research focuses on using neuroimaging and neurostimulation techniques to better understand cognition and treatment outcomes in opioid use disorder, with a particular focus on decision-making impairment in this population.

Stevie C. Britch, Ph.D
University of Kentucky

Dr. Britch is a post-doctoral fellow at the Center on Drug and Alcohol Research, Department of Behavioral Science, University of Kentucky. She completed her graduate training in 2019 at Washington State University, where her research in rodent models investigated sexual dimorphism in novel analgesics, interactions between multiple psychoactive substances, and potential immunological mechanisms underlying cannabinoid-induced reductions in inflammatory pain. During her postdoctoral training, she has transitioned to clinical pharmacology studies with a continued focus on interactions between psychoactive substances. Concurrent use of opioids with other drugs of abuse is occurring at alarming rates, however, little is understood about the safety of combining psychoactive substances. Dr. Britch’s research, with Drs. Sharon Walsh and Shanna Babaloni, aims to assess potential synergistic actions of opioid-cannabinoid and opioid-alcohol combinations on safety and abuse liability outcomes. These studies will inform the public and policy about potential dangers of combining drugs, such as alcohol or cannabis with opioids, and will also explore the potential therapeutic benefit of opioid-cannabinoid combinations on pain.

Amanda Bunting, Ph.D
New York University School of Medicine

Amanda M. Bunting, PhD is a postdoctoral fellow in the Department of Population Health in the New York University School of Medicine. She is a trainee in the Population Health Scholars program and a postdoc for CTN-0101 (PI: McNeely), assessing the efficacy of a primary care intervention for subthreshold opioid use disorder. Her research examines health disparities and substance use among justice-involved populations, with a special focus on polysubstance use involving opioids.
**Ginny Carter, Ph.D, RN**  
*University of North Carolina at Chapel Hill*

Dr. Mary Virginia Carter “Ginny” is a Research Scientist at UNC Horizons, a comprehensive drug treatment program for pregnant and parenting women and their drug-exposed children. Ginny received her PhD in Nursing from Emory University. Her work has focused on understanding the gender-related barriers to treatment and recovery both domestically and internationally. Currently she is collaborating on several studies aimed at understanding the best treatment options for women with opioid use disorders during pregnancy.

**Felipe Castillo, M.D.**  
*Columbia University & New York State Psychiatric Institute*

Felipe Castillo, MD is a current trainee in the Division on Substance Use Disorders at Columbia University Medical Center (CUMC)/New York State Psychiatric Institute (NYSPI), with training supported by an institutional NIDA-sponsored T32 training grant, under PI Dr. Frances Levin. His research interests include the treatment of substance use disorders, most prominently opioid use disorder and its associated comorbidities. He is interested in understanding better the interplay of addiction on general health effects, from cognitive capacity to utilization of medical and social services. His future directions include improving clinical trial design and execution skills as a research fellow. For this presentation to CPDD, he focused on understanding the role of baseline drug use as a moderator of treatment outcomes in a variety of currently-available MOUD treatments.

**Sarah Cercone Heavey, Ph.D, M.P.H**  
*School of Public Health and Health Professions, State University of New York at Buffalo*

Sarah Cercone Heavey, PhD, MPH is a substance use and mental health researcher. Currently, her work focuses on the intersection of intentional and unintentional opioid overdose, as well as emerging issues in the opioid overdose epidemic. Dr. Heavey completed at NIMH-funded T32 fellowship at the Center for the Study and Prevention of Suicide at the Department of Psychiatry, University of Rochester Medical Center. Prior to this, she received her MPH and PhD in Community Health and Health Behavior at the University at Buffalo, State University of New York. Dr. Heavey has worked in public health for many years, including health promotion at an insurance company and lead poisoning prevention at Women & Children’s Hospital of Buffalo. In addition, between her MPH and PhD, Dr. Heavey completed a fellowship at the Centers for Disease Control and Prevention, Office on Smoking and Health, in Atlanta, GA.

**Thomas Chao, M.A.**  
*New York State Psychiatric Institute*

Thomas Chao is a Clinical Psychology intern at the Centre for Addiction and Mental Health and a doctoral candidate from the New School for Social Research (NSSR) in New York City. He received his MA in General Psychology, with a concentration in Substance Abuse Counseling, from NSSR and his BA in Psychology from the University of British Columbia. Following his Masters, Thomas was selected for a 3-year NIDA-funded addiction research fellowship with the Substance Use Research Center, at the New York State Psychiatric Institute.
Institute. At NYSPI, he worked on projects employing drug-administration, neuroimaging, and computational methods. His current research interests are in understanding how subjective states, impulsivity, and decision-making perpetuate addictive patterns of behavior. Thomas aspires to become a clinical researcher, with an emphasis on bringing neuropsychological findings into addiction treatment.

**Tianzhen Chen, M.D.**  
Shanghai Mental Health Center

Tianzhen Chen is a Ph.D. student at Shanghai Jiao Tong University School of Medicine. Chen obtained an M.D. degree in clinical medicine from Southern Medical University in 2016. Since his Ph.D. studies, Chen’s researches have focused on the investigation of non-invasive brain stimulation treatment for amphetamine-type stimulants use disorder and related mechanism. In addition, he also focused on the processing and analysis of EEG signals. During the past 3 years, Chen has published over 20 research papers in the journals, like Addiction, Journal of Psychiatric Research, European Neuropsychopharmacology, etc. He also published several abstracts at national and international scientific conferences. Chen has also received academic awards and honors, such as Ph.D. Scholarship, National Scholarship, Travel Award, and other best paper awards in academic meetings. Currently, Chen and his mentor Dr. Min Zhao are continuing to conduct research on the underlying brain mechanism of the efficacy of non-invasive brain stimulation for drug addiction. They hope to provide important views for the clinical application of non-invasive brain stimulation.

**Vivian Chiu, Ph.D candidate**  
University of Queensland

Vivian is currently a PhD candidate at the University of Queensland, Australia. Her work surrounds the understanding the impact of international cannabis policies, with a focus on the epidemiology of cannabis and other substance use, and related consequences.

**William H. Craft, B.S.**  
Fralin Biomedical Research Institute at Virginia Tech Carilion

William is a doctoral student conducting his research at the Addiction Recovery Research Center under Dr. Warren Bickel’s Mentorship. William’s research is focused on understanding processes that may undergird addiction vulnerability as well as facilitate recovery from addiction. To that end, he is investigating the reduction of delay discounting as an opioid-sparing intervention for chronic pain. Additionally, William is involved in several projects that seek to understand the longer-term processes that facilitate successful recovery from alcohol and opioid addictions. William studied neuroscience as an undergraduate at Virginia Tech and continues his training as a part of Virginia Tech’s Translation Biology, Medicine, and Health graduate program.
Kathleen Isabel Crum, Ph.D
Medical University of South Carolina

Kathleen I. Crum, PhD is a Research Assistant Professor in the Neurosciences Department of the Medical University of South Carolina (MUSC). Dr. Crum obtained her PhD in Clinical Psychology from Florida International University. She completed her predoctoral internship through the Charleston Consortium/MUSC Traumatic Stress Track. Dr. Crum served as a Postdoctoral Researcher at Boys Town National Research Hospital's Center for Neurobehavioral Research in Children. Subsequently, Dr. Crum completed an NIMH T32 postdoctoral fellowship at the MUSC National Crime Victims Research and Treatment Center. Currently, Dr. Crum is a Career Enhancement Core Scholar as part of the MUSC Specialized Center of Research Excellence (SCORE), and serves as National Project Coordinator for Clinical Trials Network Project 108 (Transcranial Magnetic Stimulation Treatment of Cocaine/Methamphetamine Use Disorder). Dr. Crum conducts neurobiological and behavioral research on risk and resiliency following psychosocial trauma—with a focus on substance use disorders (SUDs), which are strongly associated with trauma. Her overarching long-term goal is to develop a significant program of clinical research focused on investigating neural, social, and familial factors contributing to the development of risk and resilience following stressful life events, and to inform advances in interventions to prevent or reduce adverse outcomes.

Megan E. Curtis, Ph.D
University of California, Los Angeles

Megan Curtis, PhD is a postdoctoral fellow in the Department of Psychiatry and Biobehavioral Sciences at the University of California, Los Angeles under the mentorship of Drs. Yih-Ing Hser and Larissa Mooney. Dr. Curtis is also the Node Coordinator of the Greater Southern California Node of the NIDA Clinical Trials Network and Project Manager for a NIH HEAL Initiative multisite trial (CTN-0102) that aims to expand medication treatment for opioid use disorder in rural communities through the integration of telemedicine. Dr. Curtis’s reach focuses on expanding access to evidence based treatments for co-occurring substance use disorders and chronic pain populations through technology to improve quality of life, overall functioning, and treatment retention and adherence.

Mary Kathryn (Kate) Dahlgren, Ph.D
McLean Hospital, Harvard Medical School

Dr. Mary Kathryn (Kate) Dahlgren is a post-doctoral research fellow in the Cognitive and Clinical Neuroimaging Core (CCNC) and the Marijuana Investigations for Neuroscientific Discovery (MIND) program at McLean Hospital, both led by Dr. Staci Gruber. Her work has focused on the impact of both recreational and medical cannabis use on cognition, clinical state, neural activation, and brain structure. Most recently, she published an article in Drug and Alcohol Dependence demonstrating that chronic, heavy, recreational cannabis use was associated with poorer performance on a driving simulator, even in the absence of acute intoxication (Dahlgren et al., 2020). Further, poorer driving performance was localized to early-onset cannabis users, who began regular use before age sixteen. Currently, she is working on a longitudinal project to assess driving simulator performance in medical cannabis patients before they begin using cannabis and over the course of their treatment. Her driving simulator work has been supported by the McLean Hospital Rossano Mind, Brain, and Behavior Pre-Doctoral Fellowship and the Jonathan Edward Brooking Mental Health Research Fellowship (awarded to Dr. Dahlgren in 2017 and 2020, respectively) as well as National Institute on Drug Abuse grants (awarded to Dr. Gruber).
Zheng Dai, Ph.D
West Virginia University Health Sciences Center

Zheng Dai is a post-doctoral fellow working in the Department of Epidemiology at West Virginia University. He came from China, and he has earned a BS in Bioengineering and an MS in Pharmacognosy from China Pharmaceutical University. His current research mainly focuses in drug-related injury research, including development of fatal and non-fatal drug overdose monitoring, prevention, and expansion of medication for opioid use disorder.

Amelia Dunn, Ph.D
The Rockefeller University

Amelia received her PhD in 2019 from Rockefeller University, in the lab of Dr. Mary Jeanne Kreek studying molecular and behavioral pharmacology of kappa opioid receptor agonists. She is currently a postdoctoral researcher in Dr. Julie Blendy’s lab at the University of Pennsylvania studying opioid receptor signaling in a translational mouse model of neonatal opioid withdrawal. Her overall research goal is to leverage understanding of neuropharmacology in general, and opioid receptor signaling specifically, to develop therapeutics for addictive diseases.

Jonathan Feelemyer, M.S.
New York University

Jonathan Feelemyer has been an Epidemiologist in New York City for over 10 years. He works primarily with HIV/AIDS populations and key risk groups including persons who inject drugs and racial/ethnic minorities. Mr Feelemyer has conducted research in the United States as well as Europe and Asia. He has published extensively on risks associated with HIV infection and substance use in addition to harm reduction programs and interventions. He currently is working on his PhD at NYU School of Medicine in New York City with focus on associations between illicit stimulant use and HIV viral suppression.

Alan N. Francis, Ph.D
Harvard Medical School

Dr. Alan Francis is the Louis V. Gerstner III Research Scholar/Neuroscientist at the Massachusetts General Hospital Athinoula A. Martinos Center for Biomedical Imaging and an Instructor in Psychiatry at Harvard Medical School. Dr. Francis has pursued research and teaching in the cognitive neurosciences for more than 20 years, with fellowships and teaching positions at institutions including the Indian Institute of Technology, Oxford University, Laboratory of Brain & Cognition at the National Institute of Mental Health, University of Maryland Psychiatric Research Center, Beth Israel Deaconess Medical Center, and Harvard Medical School. His area of research focused on neuroimaging and genetics of familial high risk for schizophrenia. Dr. Francis completed a Post-Doctoral Fellowship at McLean Hospital working in brain imaging and substance use disorder. He earned his PhD in Cognitive Neuroscience with high honors from Albert Ludwigs
Universitats Freiburg, Germany. He also received a masters degree in cognitive neuroscience from the University of London.

Dr. Francis was selected as a Fellow (2019 – 2021) at the Alcohol Medical Scholars Program at University of California San Diego. He was also selected for a travel award from the Schizophrenia International Research Society Annual conference April 2019 at Orlando Florida.

Erik J. Garcia, Ph.D
*University of Texas Medical Branch*

Dr. Erik J. Garcia joined the College on Problems of Drug Dependence as a Member in Training in 2019 and attended his first meeting in San Antonio, Texas in June 2019. Dr. Garcia earned his doctorate in Experimental Psychology and Behavioral Neuroscience in May 2017 from Kansas State University under the supervision of Dr. Mary E. Cain. Dr. Garcia is currently in his third year of postdoctoral training in the Center for Addiction Research at the University of Texas Medical Branch at Galveston under the supervision of Dr. Kathryn A. Cunningham. Dr. Garcia researches the extent to which selective serotonin (5-HT2C) receptor ligands affect motivated behavior using preclinical models of substance abuse. Dr. Garcia aims to identify individual differences in behavior that protect or increase the vulnerability to transition to compulsive drug consumption and use this knowledge to inform drug discovery efforts. Dr. Garcia’s long-term career goals are to mentor young scientists and maintain an active research program in substance use disorders.

Stephanie Glegg, OT, Ph.D
*The University of British Columbia*

Dr. Stephanie Glegg is a postdoctoral fellow and implementation scientist at the BC Centre on Substance Use and the University of British Columbia. Her research examines barriers and facilitators of knowledge translation/implementation, and tests interventions to support the use of evidence in health care decision-making.

Leah Hamilton, Ph.D
*NYU School of Medicine*

Leah Hamilton is a Postdoctoral Fellow in the Department of Population Health, NYU Langone Health, focusing on the intersection between justice-involvement, substance use and health. Her research uses mixed methodology to improve substance use disorder (SUD) treatment provision and health outcomes of different vulnerable populations including people on probation, drug court participants, formerly incarcerated people returning to the community and youth under community supervision.

Dr. Hamilton continues to conduct research on implementation science-informed interventions to improve screening and assessment for SUDs and appropriate treatment options for people experiencing SUDs and their associated health difficulties. She also recently joined the NYU School of Medicine Center on Opioid Epidemiology and Policy (COEP) and is conducting research on state and national policy impacts on fatal and non-fatal opioid-related overdoses.
Penelope L. Hill, BHS, MSc, GD Dev Stud, Ph.D candidate
Burnet Institute

Penelope Hill is a PhD candidate at the Burnet Institute/Monash University investigating the impact of health service use on opioid overdose among people who inject drugs (PWID) in Melbourne, due to submit her thesis in September 2020. She works as a Research Assistant within the Centre for Research Excellence into Injecting Drug Use at the Burnet Institute coordinating the National Naloxone Reference Group and as a fieldworker for the SuperMIX cohort study of PWID.

Penny has a background as a community health worker in outreach needle syringe programs across Melbourne and Sydney, and experience volunteering in festival and nightlife harm reduction services. She is a cofounder of Pill Testing Australia, and through this role established the first government supported drug checking trial in Canberra in 2018 and subsequent 2019 trial. She has also worked in festival drug checking services in New Zealand and Canada. Penny is a board member of Harm Reduction Victoria, Harm Reduction Australia, Students for Sensible Drug Policy Australia, the Vienna NGO Committee to the UN Office of Drugs and Crime and the Members Advisory Committee of the International Drug Policy Consortium.

Laura Hughes, BBiomedSc(Hons) GDipPsych
School of Psychology, Deakin University

Laura Hughes Assoc MAPS is a PhD Candidate within the School of Psychology and Cognitive Neuroscience Unit (CNU) at Deakin University in Australia. She began her career in research with an Honours Degree in Biomedical Science at Monash University, followed by a Graduate Diploma of Psychology at Deakin University. Laura has conducted research with individuals from clinical populations, such as heavy tobacco users and patients in alcohol and other drug detoxification clinics. In addition, she has worked in a community setting with those seeking treatment for alcohol and other drug use problems. Her research interests include treatments for people with tobacco and other substance use problems, psychopharmacology and cognitive neurosciences (such as executive functions). She is currently preparing her first first-author paper with data from a randomised controlled trial (RCT) for her thesis, which investigates the effectiveness of inhibitory control training (ICT) as in an intervention to assist with smoking cessation. In her spare time, Laura has volunteered as a Girl Guides Leader for over 11 years.

Charlotte Kervran, Ph.D
Université de Bordeaux

Dr. Charlotte Kervran PhD, earned an honors degree in biology-biochemistry (2011) from the University of Nantes (France) and entered a neuroscience curriculum at the University of Bordeaux (France) where she graduated with a Master’s Degree (2013) and a PhD (2019). Dr. Kervran was trained in clinical addiction research, including use of Addiction Severity Index (ASI) and Ecological Momentary Assessment (EMA) in the team of Marc Auriacombe at University of Bordeaux. Dr. Kervran acquired strong experience in subject recruitment and research assessment in treatment and harm reduction settings. Over the past 7 years, Dr. Kervran’s research included studies in sleep, craving, food and harm reduction intervention effectiveness. Dr. Kervran’s PhD research explored the stability of craving as an etiological (predictive) marker of substance use using EMA and its psychometric stability as a diagnostic criterion within the DSM-5 substance use disorder diagnostic criteria using Item Response Theory (IRT), for which she received training from Deborah Hasin at University of Columbia (NY). Dr. Kervran contributed to 5 peer-reviewed publications and 9 presentations at CPDD since 2014. Dr. Charlotte Kervran is currently a Postdoctoral Research Fellow in the Bordeaux Population Health (BPH) Center at the University of Bordeaux, Bordeaux, France.
Simeon D. Kimmel, M.D., M.A.
Boston University School of Medicine

Simeon Kimmel is an Assistant Professor of Medicine at Boston University School of Medicine and an Attending Physician in the Sections of General Internal Medicine and Infectious Diseases at Boston Medical Center and Medical Director of Project TRUST, Boston Medical Center’s harm reduction focused drop-in center. He trained in Internal Medicine and Primary Care at Brigham and Women’s Hospital before completing a joint fellowship in Addiction Medicine and Infectious Diseases at Boston Medical Center. He also earned a Master’s Degree in Medical Anthropology from the Harvard Graduate School of Arts and Sciences. His research focuses on the integration of addiction and harm reduction services with infectious disease care to improve clinical outcomes for those with and at risk for infectious and medical complications of substance use.

Elizabeth N. Kinnard, MS
UC Berkeley School of Public Health

Elizabeth (Lizzy) Kinnard is a PhD student in epidemiology at the UC Berkeley School of Public Health. She completed her bachelor’s and master’s degrees at Brown University, where she received the inaugural award for outstanding academic achievement by a master’s student. She has widely published in substance use, infectious disease, and epidemiology journals. Her research interests include substance use, drug policy, harm reduction, infectious diseases, and criminal justice involvement. Broadly, she is interested in the ways in which drug criminalization and stigma affect health outcomes among people who use drugs. She is a researcher at RTI International under the mentorship of Drs. Alex Kral and Barrot Lambdin. Elizabeth has also been very active in the advocacy and policy spaces, as a member of Students for Sensible Drug Policy and a former intern at the Drug Policy Alliance. She was an organizer for Rhode Island Governor Raimondo’s Overdose Prevention and Intervention Task Force, as well as a finalist in the Global Debate and Public Policy Challenge “Rethinking Drugs” in Budapest, Hungary. Elizabeth is committed to staying involved in both academia and public policy, ensuring that drug policies are based in rigorous scientific evidence.

Sukhpreet Klaire, M.D., CCFP
British Columbia Centre on Substance Use

Dr. Sukhpreet Klaire is an Addiction Medicine research fellow with the British Columbia Centre on Substance Use. As well, he is a practicing Addiction Medicine and Family Medicine physician, working with urban and marginalized populations in Vancouver, Canada. He completed medical school at McMaster University, residency training at the University of Ottawa, and a clinical fellowship with the British Columbia Centre on Substance Use. His clinical and research interests include community-based harm reduction initiatives, the integration of addiction with primary care services, and the exploration of novel treatment approaches for opioid use disorder.
Elias Klemperer, Ph.D
Vermont Center on Behavior and Health

Elias Klemperer completed his PhD in clinical psychology in 2019 and is currently a NIDA T32 post-doctoral trainee with the Vermont Center on Behavior and Health at the University of Vermont. His research primarily focuses on interventions and policies to address nicotine and tobacco use among people who are not engaged in treatment. This year, Eli is presenting research at CPDD on predictors of smoking cessation attempts and success among people initially not ready to quit smoking. Eli’s ongoing research is on strategies to reduce harm from cigarette smoking among people who also use e-cigarettes.

Emanuel Krebs, M.A.
Health Economic Research Unit at the BC Centre for Excellence in HIV/AIDS

Emanuel Krebs is a Senior Health Economist for the Health Economic Research Unit at the British Columbia Centre for Excellence in HIV/AIDS, a Research Affiliate with the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH), a member of The Opioid Use Disorder Modeling Writing Group collaboration to inform policy modeling, the holder of a 2020 Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Research Award from the Canadian Institutes of Health Research and the recipient of the Dr. Mowafaghian Doctoral Fellowship in the PhD program at the Faculty of Health Sciences at Simon Fraser University. He has expertise specializing in applied econometrics using health administrative data and model-based health economic evaluation, and his research has spanned economic evaluations in HIV/AIDS and opioid use disorder.

Soeren Kuitunen-Paul, Dipl.-Psych.
Department of Child and Adolescent Psychiatry, Faculty of Medicine, TU Dresden, Dresden, Germany

Soeren Kuitunen-Paul is a clinical psychologist who specialized in addiction science. He graduated from the TU Dresden (Germany) where he also earned his doctoral degree. His current research interests are psychometric evaluation of instruments, relapse prediction, use motives and objective validation of subjective substance use reports. After focusing on alcohol in young adults in the past, he now focusses on cannabis, methamphetamine and nicotine use in adolescents with SUD. He also served as peer reviewer for several journals on addiction and psychiatric methods, including Addiction, IJMPR, SUCHT, Psychological Medicine, PMC Public Health, as well as Drug and Alcohol Dependence. Furthermore, he is active in a local initiative promoting the de-stigmatization of persons with mental disorders, and published background chapters in two children books dealing with anxiety disorders in children as well as with children of alcohol-abusing adults.

Jessica A. Kulak, Ph.D, M.P.H
Buffalo State College

Jessica A. Kulak is an Assistant Professor in the Department of Health, Nutrition, and Dietetics at Buffalo State College. She has published peer-reviewed journal articles on smoking cessation patterns among African Americans, the emerging use of hookah among young people, tobacco control policies, and research guidelines for monitoring the global tobacco use epidemic. Her current research focuses on at-risk populations and the risk and resiliency factors related to substance use. Jessica holds a Master’s degree in School and Community Mental Health Counseling from
the University of Rochester and a Master of Public Health from the University at Buffalo (UB). Jessica received her PhD from the School of Public Health and Health Professions at UB in 2017.

**Laura Lambert, Ph.D student**  
*University of Bordeaux*

Mrs. Laura Lambert is a predoctoral PhD student in the neuroscience curriculum at the University of Bordeaux (France). She earned an honors degree in biology (2015) and graduated with a master’s degree in neuroscience (2017). Mrs. Lambert’s research training curriculum is in human addiction research in the team of Marc Aurelacoome at University of Bordeaux (SANPSY CNRS USR 3413 where she acquired expertise in Addiction Severity Index (ASI) and Ecological Momentary Assessment (EMA). Mrs. Lambert’s research examines how insight level (understanding and acceptance by the patient of addiction) could interfere with the etiological/prognostic role of craving on use and relapse. She will present her first results at the CPDD 2020 poster session. Mrs. Lambert is actively involved in scientific mediation with Bordeaux Neurosciences Association and is event manager for the international festival of Pint of Sciences since 2018. In March 2020, Mrs. Lambert was in the final selection of the Three Minute Thesis (3MT) competition from 16 PhD student candidates of the University of Bordeaux. Mrs. Lambert is funded by a grant from the Aquitaine Regional Council.

**Danni Lanaway, Ph.D**  
*Atlanta VAMC/Emory University School of Medicine*

Dr. Danni Lanaway completed her doctoral degree in Clinical Psychology at the University of Cincinnati. Her research has focused on psychosocial factors that influence substance use, as well as the cultural adaptation of psychosocial interventions. In both her research and clinical work, she serves underrepresented and minority populations, with the goal of providing culturally relevant care to target and reduce mental health disparities.

**Antoine Lebeaut, M.A.**  
*University of Houston*

Antoine is a rising third-year doctoral student in the clinical psychology doctoral program at the University of Houston and is advised by Dr. Anka Vujanovic. He received his B.A. in psychology from Franklin & Marshall College in 2015. Following graduation, Antoine has held research assistantships at Fordham University, working under the supervision of Dr. Dean McKay, and Rutgers University Behavioral Health Care, working under the supervision of Dr. Steven Silverstein. Recently, he has worked as a pre-doctoral clinician at the University of Houston’s Lone Star Circle of Care clinic, a federally qualified health center, and will begin working as a pre-doctoral clinician with the Houston Fire Department in August 2020. He received his M.A. in clinical psychology from the University of Houston in 2019. Antoine’s current research interests involve examining the role of transdiagnostic factors, particularly anxiety sensitivity, in the development and maintenance of co-occurring PTSD and substance use, with a focus on alcohol use disorder.
Juhan Lee (John), B.A.
University of Florida

Juhan Lee (John) is a 4th year Ph.D. student in Health Behavior at the University of Florida. His research interests focus on statistical methodology in longitudinal data analysis (especially in structural equation modeling and mixture modeling) on tobacco use and cessation pattern among (1) youth and (2) individuals with cancer or (3) substance use disorder.

Anna Liley, M.S.
The University of Memphis

Ms. Liley is a first generation graduate student from Memphis, TN, and is currently working on her PhD at the University of Memphis. She has always been interested in helping people with substance use disorders, and applied to graduate school after developing a passion for neuroscience in her undergraduate career. Her primary research goal is to explore how rewards and consequences are evaluated to guide decision-making, with the long-term goal of developing neurobiological treatments to improve decision-making in individuals with substance use disorder.

Lewei (Allison) Lin, M.D., M.S.
University of Michigan

Allison Lin, MD, MS is an addiction psychiatrist and Assistant Professor in the Department of Psychiatry and a research investigator at the VA Center for Clinical Management Research at VA Ann Arbor. She investigates ways to improve access and quality of care for patients with opioid and other substance use disorders (SUDs). She conducts studies using large electronic health datasets to evaluate disparities in SUD treatment and intervention studies, in particular telehealth-delivered interventions, to improve access to treatment and outcomes for patients with SUDs.

Jingxin Liu, M.P.H
Miller School of Medicine, University of Miami

Jingxin Liu has obtained MPH degree at UC Colorado Denver, and now is pursuing PhD in Epidemiology at the University of Miami. Jingxin has been working on HIV/AIDS prevention, Marijuana related research and Cancer Epidemiology for years since 2017. She is experienced in data manipulation and analysis, especially with survival, longitudinal, multi-level, and cross-sectional types of data.
Shawnta L. Lloyd, M.P.H
University of Florida

Shawnta Lloyd is a doctoral candidate in the Department of Epidemiology at the University of Florida in Gainesville, Florida. Prior to enrolling at the University of Florida, she received a Bachelor of Science in Chemistry from Hampton University in Hampton, Virginia and a Master of Public Health in Epidemiology from Emory University in Atlanta, Georgia. Additionally, Ms. Lloyd worked in the federal government for four years in research administration at the Food and Drug Administration and the Veterans Health Administration. Her research interests include substance use and mental health among middle-aged and older adults. She has co-authored four manuscripts related to substance use and mental health. As a doctoral student, she has participated in primary data collection and secondary analyses of existing data sets on substance use. Her training has previously been funded by the National Institute on Drug Abuse T32 program through the University of Florida Substance Abuse Training Center in Public Health. Currently, Ms. Lloyd is a McKnight Doctoral Fellow and a Graduate Assistant in the Department of Epidemiology at the University Florida.

Laura MacKinnon, M.D.
University of British Columbia

Dr. Laura MacKinnon completed her medical school and residency training in family medicine with the University of British Columbia, Canada. She has experience providing primary care and substance use disorder treatment in Vancouver’s Downtown Eastside and in rural and remote Indigenous communities in British Columbia. She is currently a research fellow with the BC Center on Substance Use (International Collaborative Addiction Medicine Research Fellowship) and has a primary interest in the field of housing-related research.

Caitlin E. Martin, M.D., M.P.H
Virginia Commonwealth University

Caitlin Eileen Martin is a board certified Obstetrician-Gynecologist and Addiction Medicine provider at Virginia Commonwealth University in Richmond, Virginia. She received her B.S. at the University of North Carolina Chapel Hill followed by her Master’s in Public Health and Medical Degrees from the Johns Hopkins Schools of Medicine and Public Health. She completed her residency training in Obstetrics and Gynecology at the University of North Carolina Chapel Hill and will obtain her Addiction Medicine board certification next year. Clinically, she is the Director of OBGYN-Addiction Services at VCU and leads their program providing integrated care for pregnant and parenting women with substance use disorders. As a physician scientist, her primary research interests lie at the intersections between addiction, gender, reproductive and sexual health as well as pain.

Caravella McCuistian, Ph.D
University of California, San Francisco

Caravella McCuistian is currently a clinical psychology postdoctoral fellow at University of California, San Francisco. She received her doctoral degree in psychology from the University of Cincinnati in August 2019. Her research interests include addressing health disparities among underserved populations including racial/ethnic minorities, women, individuals living with HIV, and substance-using populations. She has conducted research that
utilizes community-engaged methodology, including Community-Based Participatory Research, to develop behavioral interventions to improve sexual health. These interventions target HIV prevention and sexual risk reduction in a culturally-informed way for women who use substances as well as women engaged in transactional sex. Dr. McCuistian is also interested in addressing health disparities in novel ways and has contributed to research aimed at developing interventions for individuals within substance use treatment facilities as well as leveraging technology to provide interventions to underserved communities.

Alexandra Mellis, Ph.D
New York University School of Medicine

Dr. Alexandra Mellis is a decision neuroscientist studying health behavior and addiction. In her PhD work with Warren K. Bickel at Virginia Tech, she examined the interaction of risk factors for negative health behaviors, using functional neuroimaging and behavioral methods with a focus on alcohol use, nicotine use, and prediabetes. Her postdoctoral work with Paul W. Glimcher at the New York University School of Medicine employs computational and decision neuroscience to examine how behavioral risk factors change with environmental contexts, using functional neuroimaging and intensive longitudinal methods with a focus on patients receiving medications for opioid use disorder. Her research has specifically examined the impact of environmental shocks and stressors on the valuation of substances of abuse, and identification of decision-making variables as candidates for translation to clinically-relevant outcomes.

Christina R. Merritt, B.S.
University of Texas Medical Branch

Christina Merritt completed her Bachelor of Science degree in Psychology at Virginia Commonwealth University where she graduated magna cum laude. Ms. Merritt was heavily recruited to the Pharmacology and Toxicology graduate program at the University of Texas Medical Branch in 2016, and was offered the highly competitive Presidential Scholars Award. She is currently conducting her dissertation research under the mentorship of Dr. Kathryn A. Cunningham in the Center for Addiction Research. Her dissertation is focused on elucidating the mechanisms in which striatal serotonin 2C receptors (5-HT2CR) regulate neurocircuitry critical to opioid reinforcement. Ms. Merritt is currently funded under the Jeane B. Kempner Award, has published five peer-reviewed manuscripts, and has attended twelve local, national, and international conferences. Upon completion of her dissertation research, Ms. Merritt will seek a postdoctoral fellowship to continue investigating the neuropharmacology of substance use disorders and their treatment. Ms. Merritt’s long-term career goal is to become a tenured Professor at an academic institution, leading a translational research program focused on the prevention and treatment of SUDs.

Barrett Wallace Montgomery, B.S.
Michigan State University

Barrett Montgomery is a second-year Ph.D. student in the Department of Epidemiology and Biostatistics at Michigan State University. His research portfolio blends creative uses of urban administrative data, substance use prevention, and public policy work based in Boston, New York City, and Flint. He is a 2018 recipient of the Michigan State University Enrichment Fellowship and the 2020 American Psychopathological Association Distinguished Fellow Memorial Awardee. His primary interests are the environmental and social influences on drug use, how to measure these effects, and how they affect
the most vulnerable populations. He is especially interested in the translation of these findings to policy, and policy itself as a mutable component of environmental influence.

**Benjamin J. Oldfield, M.D., M.H.S.**  
*Yale School of Medicine*

Dr. Oldfield is clinical instructor of medicine and pediatrics at Yale School of Medicine, Core Faculty of the Yale National Clinicians Scholars Program, and Chief Medical Officer at Fair Haven Community Health Care, a federally qualified health center in New Haven, CT. His work focuses on access to treatment for underserved populations, integrating care for substance use disorders with their infectious complications, implementation of harm reduction strategies, and substance use among adolescents.

**Alexandra N. Palmisano, Ph.D.**  
*Yale University*

Alexandra N. Palmisano, PhD is a psychologist completing postdoctoral training at Yale University supported by a National Institute on Drug Abuse T32 Fellowship. She received her PhD in Behavioral Neuroscience from the University of Connecticut in 2019. Her doctoral work utilized translational virtual reality (VR) tasks to examine the effects of nicotine on human conditioned learning. Her current work investigates neuropsychological factors important to those with comorbid substance use and psychiatric disorders. Her specific areas of research include (1) developing a novel, translational VR behavioral avoidance task to investigate the relationship between alcohol use disorder (AUD) and PTSD, (2) evaluating the efficacy and physiological effects of sublingual buprenorphine combined with extended-release naltrexone in the treatment of comorbid AUD and PTSD, and (3) examining the epidemiology of substance use and comorbid PTSD among a large, nationally-representative U.S. veteran sample.

**Kelly Peck, Ph.D.**  
*University of Vermont*

Kelly’s research and clinical interests are two-fold. First, he is conducting research focused on the development and evaluation of novel treatments for opioid misuse and use disorder. Most recently, this has included two randomized clinical trials evaluating a novel interim buprenorphine treatment (IBT) for reducing illicit opioid use and other high-risk behaviors among adults with untreated opioid use disorder (OUD). He also has experience conducting clinical research aimed at preventing and treating opioid and other medication misuse among a variety of vulnerable populations, including adolescent and young adult oncology patients as well as chronic headache patients in rural Mississippi. Second, he has worked extensively with individuals with concurrent substance use disorders and posttraumatic stress disorder (PTSD), particularly around the delivery and evaluation of cognitive-behavioral treatments for PTSD (Peck, Coffey, McGuire, Voluse, & Connolly, 2018; Peck, Schumacher, Stasiewicz, & Coffey, 2018). Currently, he is the project director on an ongoing randomized trial designed to investigate the contribution of a manualized cognitive-behavioral treatment for reducing PTSD severity above and beyond opioid agonist therapy alone for reducing PTSD symptomatology among adults with concurrent PTSD and OUD.
Rajiv Radhakrishnan, M.B.B.S, M.D.
Department of Psychiatry, Yale School of Medicine

Dr. Rajiv Radhakrishnan MBBS, MD is an Assistant Professor of Psychiatry at Yale University School of Medicine. He is board-certified in Psychiatry and Addiction Medicine. As a physician-scientist with a research interest in examining the effects of cannabinoids, he has conducted laboratory studies using THC and is currently examining the effects of cannabidiol on brain microglial activation using positron emission tomography (PET) imaging in a NIH-funded study. His poster at the CPDD meeting examines synaptic vesicle density in cannabis-use disorder using the PET ligand \([11C]UCB\)-J, and the relationship with cognition.

Claudia Rafful, Ph.D.
Faculty of Psychology, Universidad Nacional Autonoma de Mexico

Dr. Claudia Rafful obtained her PhD degree from the UCSD-SDSU Joint Doctoral Program in Public Health. She is a psychologist with >10 years’ experience on epidemiological mental health and substance use research, both in the United States and in Mexico. She is currently Assistant Professor at the Faculty of Psychology at Universidad Nacional Autónoma de México (UNAM), and a researcher at the Center for Global Mental Health Research at the National Institute of Psychiatry, both affiliations in Mexico City. Dr. Rafful has been an AITRP pre-doctoral fellow and a Canadian Institutes of Health Research (CIHR) postdoctoral fellow. Her research focus has been injection drug use and social determinants of health in the Mexico- US border. After her return to Mexico, she has developed independent research areas, including the first epidemiological study on crystal methamphetamine use in Mexico City, for which she is the PI. To date, Dr. Rafful has collaborated on 32 publications.

Timothy Regan, M.A.
Texas A&M University

Timothy Regan is a fourth-year Ph.D. student in the Clinical Psychology program at Texas A&M University. Specializing in addiction, he has particular interests in the role of executive dysfunction in substance abuse and addictive behaviors. Timothy's research often examines how diversity variables interact with impulsivity-related constructs to affect prevention and treatment outcomes for vulnerable populations. His dissertation focuses on the potential for technology-based video game interventions to assess and "re-train" attentional control in heavy alcohol drinkers. Outside of research, he has worked as a trainee therapist and assessment evaluator in outpatient and correctional facility settings. Timothy aims to leverage his blended skill-sets in clinical and research work to secure a well-rounded clinical psychology internship offering training in substance abuse-related assessment and treatment.

Jennie Ryan, Ph.D, CPNP-AC
University of Michigan

Dr. Jennie Ryan is a Certified Pediatric Nurse Practitioner and a Postdoctoral Research Fellow at the Center for the Study of Drugs, Alcohol, Smoking and Health (DASH) at the University of Michigan School of Nursing. Her fellowship is funded by the T32 Complexity: Innovations in Promoting Health and Safety. Dr. Ryan’s research training, under the direction of Drs. Carol Boyd and Sean McCabe, focuses on the use of large data sets to examine the effects of public policy on public health. She is particularly interested in the effects of cannabis legalization on adolescent health outcomes. Dr. Ryan
Stephen Scroggins, M.Sc.
Saint Louis University

Stephen is currently a doctoral student at Saint Louis University at the College for Public Health and Social Justice in the Department of Behavioral Science and the GeoSLU institute. Stephen’s research focus is studying the role that location plays in identifying behavior of vulnerable and marginalized populations, including those living with substance use disorder. Prior to starting his doctoral program, Stephen was an HIV disease investigator for the City of Saint Louis Department of Health and the Indiana State Department of Health Newborn Screening Investigator/Coordinator. Stephen loves collaborating and believes it to be the backbone of innovative research. Stephen has a long history of working for and with communities to address and resolve structural barriers in health access and availability.

Kristin Serowik, Ph.D
Yale University, Department of Psychiatry

Dr. Serowik is a clinical psychology postdoctoral fellow at VA Connecticut/Yale University School of Medicine. She is currently a first year in the Interprofessional Advanced Fellowship in Addiction Treatment, receiving mentorship from Drs. Steve Martino and Marc Rosen. Broadly, her research targets the treatment engagement process for addiction, including identification of substance use disorders, engagement, and treatment retention. Implementation science has been a primary focus of her fellowship studies. She is actively engaged in research targeting implementation efforts for evidence-based interventions for individuals with co-occurring substance use and chronic pain, as well as examining the delivery of substance use treatment by telehealth. Additionally, she is investigating factors that influence the implementation of efficacious treatments, which may inform policies aimed at maximizing treatment engagement and enhancing treatment outcomes.

Justin M. Shepherd, M.A.
University of Houston

Justin Shepherd is a second-year doctoral student in the Clinical Psychology program at the University of Houston and a Graduate Research Assistant in the Anxiety and Health Research Laboratory/Substance Use Treatment Clinic. He has published over 25 peer-reviewed articles and book chapters on risk and protective factors of addictive behavior (including tobacco, electronic cigarette, opioid, alcohol, cocaine, and cannabis use) in relation to clinically relevant treatment and negative health-related outcomes. Mr. Shepherd’s line of research focuses on identifying risk factors for addiction using a biopsychosocial approach. His long-term professional scholarly interests include elucidating psychosocial mechanisms of action (e.g., pain-related anxiety, anxiety sensitivity, emotion dysregulation) for substance use problems among comorbid populations (e.g., chronic pain, mental health disorders), including among racial and ethnic minority groups.
Dennis Sholler, Ph.D
Joens Hopkins University School of Medicine

Dennis Sholler is a postdoctoral fellow in the Behavioral Pharmacology Research Unit and Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine. Dennis completed his PhD in Pharmacology and Toxicology at the University of Texas Medical Branch, where he used preclinical models to explore the serotonin 2A receptor in impulsive action and drug-seeking behaviors. Dennis joined the laboratory of Dr. Ryan Vandrey at Johns Hopkins University to study the behavioral pharmacology of cannabis and cannabinoids using controlled laboratory studies with adult research volunteers, clinical trials, and online survey research.

Cho-Hee Shrader, M.P.H
Miller School of Medicine, University of Miami

Cho-Hee Shrader, MPH, is a Prevention Science and Community Health doctoral candidate at the University of Miami Miller School of Medicine. Ms. Shrader is a substance use and HIV health disparity researcher. She uses social network analysis methodologies and geospatial technology (GIS) to address how the substance use and HIV syndemic affects sexual and ethnic minority communities. Her dissertation explores how cultural and immigration-related factors affect the social network configurations of Latino men who have sex with men, and how these configurations influence the spread the PrEP information within networks. She then expands on these network models with geospatial analysis. Ms. Shrader also coordinates several of her mentor’s, Dr. Mariano Kanamori’s, programs including PrEParados, PROGRESO, and FINISHING HIV (Florida South Hispanic Network Fighting HIV).

Background and education: Ms. Shrader began her BS at the University of Cape Town in South Africa, then received her diploma from the University of Iowa in Health and Human Physiology. She obtained an MPH in Global Health with a concentration in Sexual and Reproductive Health at Emory University. She has worked in five countries on various public health projects.

Chang (April) Shu, Ph.D
Yale Department of Psychiatry

April Shu is a psychiatric geneticist interested in functional genomics, single-cell technology, statistical genetics and machine learning. April received multidisciplinary training in Biology, Genetic Epidemiology, Mental Health, Biostatistics and Bioinformatics.
Kelsey A. Simpson, M.A.
Keck School of Medicine, University of Southern California

Kelsey Simpson is a 3rd year doctoral student in the Health Behavior Research PhD program at the Keck School of Medicine at the University of Southern California. Prior to beginning her doctoral studies at USC, Kelsey received an MA in Clinical Psychology from California State University Northridge with honors in May of 2016, and a BA in Psychology from University of California Santa Cruz in June of 2012. Kelsey has conducted health disparities and addiction-related research in varied contexts with diverse populations. As a master’s student, she conducted laboratory-based neurocognitive research examining neuropsychological functioning and health disparities in HIV positive individuals. As a doctoral student, she has participated in qualitative and quantitative research projects with young adult cannabis and tobacco users, people who inject drugs, and gay and bisexual Latinx emerging adults. Kelsey’s primary research interests are grounded in investigating addictive processes, and the role of socioeconomic, psychological, social, and environmental conditions implicated across the substance use trajectory. She is also interested in topics such as psychiatric comorbidities, access to treatment, HIV and HCV related health risk, poly-substance use, and injection risk behaviors.

Lia J. Smith, M.A., L.P.A.
University of Houston

Lia is a fifth-year clinical psychology doctoral student and teaching fellow at the University of Houston. She is advised by Drs. Clayton Neighbors and Matthew Gallagher. Lia’s research interests focus on risk (e.g., sleep, distress tolerance) and resilience (e.g., mindfulness, psychological flexibility) processes at the intersection of addictions, trauma, and health disparities. Recently, she was awarded an NIAAA F31 Predoctoral Fellowship (Parent F31) for her study entitled, An Examination of the Effects of Global Sleep Disturbance and PTSD on Alcohol Cue Reactivity.

Aaron P. Smith, Ph.D
University of Kentucky

Dr. Smith’s graduate training focused on the process of how individuals value rewards that may lead to conditions such as substance use disorder. Utilizing psychological and economic theories, Dr. Smith researched how environmental factors influence and interact with neurobiological processes to alter the propensity for individuals to make impulsive, risky, or suboptimal decisions. Now in his postdoctoral work, Dr. Smith seeks to translate his preclinical findings to human research towards the goal of aiding in requisite treatment strategies for conditions that may stem from imbalanced reward valuation.
Michael J. Sofis, Ph.D
Geisel School of Medicine at Dartmouth

Michael Sofis is an NIH T-32 postdoctoral fellow at the Center for Technology and Behavioral Health (CTBH). Michael graduated with a PhD in Behavioral Psychology at the University of Kansas in 2018, where he primarily researched the behavioral economics of self-control and persistence. At CTBH, Michael works with Dr. Alan Budney to examine behavioral economic underpinnings associated with substance use and other health behavior. Recently, Michael's research interests have evolved to focus on targeting excessive discounting of delayed rewards and deficits in episodic memory using a novel treatment that combines episodic specificity training and episodic future thinking to reduce cannabis use.

Philip Spechler, Ph.D
Laureate Institute for Brain Research

Philip received his Ph.D in Experimental Psychology at the University of Vermont in 2019. He was a student of Dr. Hugh Garavan and studied the neurobiological predictors and consequences alcohol, tobacco, and cannabis use in vulnerable populations. He is currently a post-doctoral research associate at the Laureate Institute for Brain Research with Dr. Martin Paulus.

Nichole E. Stetten, Ph.D, M.P.H, C.P.H
University of Florida

Dr. Stetten is a Research Assistant Professor in the Department of Occupational Therapy in the College of Public Health and Health Professions at the University of Florida. Dr. Stetten recently completed an NIAAA T32 Post-Doctoral Fellowship in Epidemiology. Her research aims to reduce substance use among individuals living with a disability. Her current research focuses on how marijuana use affects tobacco, alcohol, and opioid use among people with disabilities.

D.W. Svenson, B.A.
Wayne State University

D.W. Svenson is currently a second-year neuroscience graduate student at Wayne State University (Detroit, MI). Under the advisement of Dr. Scott E. Bowen, one of the foremost inhalant researchers, D.W. has developed a theoretical and technical understanding of inhalant & drug abuse with a specific focus on behavioral pharmacology & toxicology. The Bowen lab utilizes a host of behavioral assays; gas chromatography to measure solvent concentrations in rodent blood and tissue; and in vitro histological imaging techniques. D.W.’s thesis project aims to explore the toxicological profile of toluene, an aromatic hydrocarbon, in the lung and brain. Interdepartmental collaborations between Psychology and the School of Pharmacy have allowed him access to the resources necessary to learn and perform the histological techniques necessary to complete his project. His preliminary findings earned him
a competitive award at the Graduate Student Poster Day (WSU Psychology Dept.). D.W. is currently in the process of preparing an F31 grant and applying for additional funding.

**Devin C. Tomlinson, B.S.**  
*Fralin Biomedical Research Institute at VTC*

Ms. Tomlinson is a second-year graduate student in Virginia Tech’s interdisciplinary Translational Biology, Medicine, and Health program in the lab of Dr. Warren K. Bickel. Ms. Tomlinson’s work with Dr. Bickel primarily focuses on Alcohol Use Disorder and the recovery process of Substance Use Disorders. She is involved with many projects examining the substance use disorders and recovery, including: The International Quit and Recovery Registry, Transcranial Magnetic Stimulation for opioid use disorder, and alcohol self-administration. While at Virginia Tech, she also completed research rotations with the departments of neurosurgery and psychiatry and behavioral medicine at Carilion Clinic.

Ms. Tomlinson comes to Virginia Tech from Oakland University, where she graduated Magna Cum Laude as a Presidential Scholar from the Honors College. Her research interests include Addiction, Psychiatric Disorders, Behavioral Economics, and Science Policy.

**Aaron Tryhus, B.S.**  
*Wake Forest University School of Medicine*

Aaron Tryhus graduated in 2018 from the University of Wisconsin-Eau Claire where he first gained a passion for behavioral pharmacology working under Dr. David Jewett. After finishing his undergraduate degree, he started in the Integrative Physiology and Pharmacology PhD program at Wake Forest Graduate School of Arts and Sciences. He currently works in the lab of Dr. Paul Czoty studying the behavioral and neural interactions of short term and long term cocaine and alcohol co-abuse. Aaron is also involved in Students for Sensible Drug Policy where he acts as the vice president of the Wake Forest School of Medicine chapter that was formed this past school year. As a future career, Aaron is interested in going into science policy or science writing.

**Alyssa Vanderziel, M.S.**  
*Mishigan State University Department of Family Medicine*

I am currently an Epidemiology Ph.D. Candidate in the Department of Epidemiology & Biostatistics at Michigan State University College of Human Medicine (MSU CHM). My research interests are in drug dependence/behavioral epidemiology, with a focus on the health effects of cannabis use. My primary graduate advisor is Dr. Omayma Alshaarawy in the Department of Family Medicine at MSU CHM. I received my B.S. in Biochemistry from Oakland University, located in Rochester Hills, Michigan. I then received my M.S. in Epidemiology from the Department of Epidemiology & Biostatistics at MSU CHM before pursuing my doctoral degree.
Adam Viera, M.P.H
Yale School of Public Health

Adam Viera is a PhD candidate at the Yale School of Public Health, Department of Social and Behavioral Sciences, where his research focuses on the development and implementation of evidence-based interventions to address substance use and related health issues, such as HIV, hepatitis C, and overdose. His dissertation research focuses on the development of an app-based intervention to support maintenance of recovery in the face of environmental triggers. He has over 15 years of experience in the public health field working to address HIV and substance use, with over a decade of experience providing capacity building assistance services at the national, regional, and local levels.

An Ye, Ph.D
Baylor College of Medicine

Dr. Ye have a broad background in human/mouse genetics, pharmacogenetics, addiction and psychiatric genetics, molecular biology, and bioinformatics. His research includes genetic/epigenetic changes associated with the vulnerability to develop osteoporosis in menopausal woman, autism spectrum disorder and imprinting gene disease (angelman syndrome). His research has uncovered that genetics/epigenetic factors and environmental factors play an important role in the vulnerability to develop these diseases. His current research focuses on genetic and epigenetic mechanisms determining response to drug addiction and psychiatric disorders, including bipolar disorder, traumatic brain injury and suicide. He found that genetic variants may determine gene expression level, and ultimately change the vulnerability to drug addiction. In addition, epigenetic factor also plays an important role on drug addiction and psychiatric disorder diseases. For instance, he discovered 9 microRNAs shown significant association with suicidal ideation. These studies may give clinicians a more objective initial screening tools for drug addiction and psychiatric disorder diseases.

Shalini Arunogiri, M.B.B.S (Hons), Ph.D, MPsychiatry M.Sc., FRANZCP Cert Addiction Psychiatry
Monash University

Dr Shalini Arunogiri is a medical practitioner, addiction psychiatrist and early-career clinician researcher. Dr Arunogiri has had 35 refereed publications and over 0.5M in chief investigator funding to date. Her PhD investigated the cognitive correlates of methamphetamine psychosis, and her research program now has a focus on stimulant use, and women’s health and addiction. She is also an investigator on three current clinical trials of treatment for opioid and stimulant use disorders.

Clinically, Dr Arunogiri leads a team of over 50 multidisciplinary staff in delivery of addiction treatment. She
holds leadership roles in Australian addiction policy and practice, as Chair of the Royal Australian and New Zealand College of Psychiatrists Binational Faculty of Addiction Psychiatry, and as Co-Chair of the Policy and Practice Interest Group at the International Society of Addiction Medicine (ISAM). Dr Arunogiri is passionate about advocating against stigma in addiction. She is active on Twitter (@SArunogiri) and is Social Media Editor for the American Journal of Drug and Alcohol Abuse (AJDAA) and ISAM. She is also a proud mother of a four year old boy.

**Tara Bautista, Ph.D**
*Arizona State University*

Dr. Tara Bautista completed her undergraduate studies at San Diego State University – Imperial Valley Campus in Calexico, California where her research and training centered around Latinx/Hispanic Health Psychology. She earned a transdisciplinary Ph.D. from the College of Nursing and Health Innovation at Arizona State University. Her dissertation study examined the acceptability of a mindfulness-based intervention for women with trauma in treatment for substance use disorder. More broadly, her research assesses factors that influence acceptability and inform evidence-based adaptation for specific subgroups to improve fit and implementation of interventions to address substance use disorders and other health disparities.

**Emilie Bruzelius, M.P.H**
*Columbia University Mailman School of Public Health*

Emilie Bruzelius is PhD student in the Department of Epidemiology. Her research integrates approaches from epidemiology and data science to examine how social policies influence health outcomes with a focus on substance use and health disparities. Emilie is currently working on research examining the joint effects of cannabis and prescription opioid legislation on chronic pain and substance use outcomes. Her dissertation research explores intersections between the opioid crisis, criminal justice policies and child welfare outcomes.

**Julien Dodu, B.Sc.**
*Virginia Commonwealth University*

Julien Dodu is a current PhD candidate in the department of Pharmacology and Toxicology at Virginia Commonwealth University. Before joining VCU in 2017, Dodu completed his bachelor’s conducting drug abuse research related to the endocannabinoid system. In 2018, under the guidance of Dr. Aron Lichtman, Dodu began research on CB1 positive allosteric modulators and their potential application in opioid withdrawal. He is honored to receive CPDD’s Women & Sex/Gender Junior Investigator award and is excited to present his recent findings.
Michelle Doyle, B.S.
University of Texas Health Science Center at San Antonio

Michelle Doyle is a graduate student in the Department of Pharmacology at UT Health San Antonio. She earned her bachelor’s degree from Tufts University, where she conducted research on the interaction between stress and stimulant use with Dr. Klaus Miczek, and subsequently worked as a research assistant at McLean Hospital/Harvard Medical School with Drs. Raj Desai and Jack Bergman to investigate the behavioral and neurochemical effects of nicotine and other stimulants. In Dr. Greg Collins’ lab at UT Health, Michelle is interested in understanding factors contributing to individual differences in vulnerability to developing a substance use disorder, or SUD-like phenotype. Her research examines the role of sex, access condition, dopamine D3 receptors, and serotonin 2C receptors in aberrant drug-taking behavior in rats.

Daniel Farkas, B.S.
Temple University School of Medicine

Daniel Farkas is a Biomedical Sciences Ph.D. Student within the laboratory of Dr. Scott Rawls in the Center for Substance Abuse Research at the Lewis Katz School of Medicine at Temple University located in Philadelphia, PA. His research primarily focuses on understanding the therapeutic and pharmacological profiles of the alkaloid constituents of Kratom (Mitragyna Speciosa). Specifically, his work focuses on characterizing the neuroprotective efficacy and pharmacological mechanism of the kratom alkaloid mitragynine in a preclinical model of chemotherapy-induced peripheral neuropathy (CIPN). Daniel Farkas’ background in scientific research is heavily rooted in behavioral pharmacology and rodent models of chronic pain, and has prior research experience investigating alternative plant-derived compounds such as phytocannabinoids in the context of chronic pain and inflammation. His ultimate career goal is to work in the scientific communications industry as a medical science liaison.

Jessica M. Illenberger, M.A.
University of South Carolina

Jessica Illenberger, M.A., is a graduate student of experimental psychology at the University of South Carolina and has been a research member of the Brain and Behavior Laboratory since beginning as an undergraduate in 2014. In addition to special interests in the statistical analysis of behavioral data, Jessica’s research focuses on factors (such as biological sex, environment, and fronto-striatal circuit integrity) which interact with learning and goal-directed processes and how such factors contribute to drug addiction. Her dissertation research involves using DREADDs to alter reward circuit activity in male and female control rats, as well as rats with preexisting HIV1-induced reward dysregulation, during sucrose and cocaine-related choice testing. Her training has been partially supported by the Psychology Department, the Brain and Behavior Laboratory, and by the T32 Behavioral Biomedical Interface Program (BBIP) emphasizing multidisciplinary collaboration in behavioral and biomedical research. Several of her projects have also received funding or travel awards provided by her department, the BBIP, and the College on Problems of Drug Dependence. Jessica aims to progress to a postdoctoral research position focused on informing the development of innovative behavioral and biological methods to interfere with the development and maintenance of addiction and/or other behavioral dysfunctions.
Natalie Levy, M.P.H  
*Columbia University Mailman School of Public Health*

Natalie Levy is a doctoral student in the Department of Epidemiology at the Columbia University Mailman School of Public Health where she also serves as a graduate research assistant to Dr. Silvia Martins. Prior to beginning the doctoral program, Natalie worked at the New York City Department of Health and Mental Hygiene for several years where she developed expertise in the management and analysis of complex datasets, study design, data collection, and program evaluation. Natalie’s current research focuses on the effects of medical marijuana laws on patterns of cannabis initiation, use, and perceptions; the particular effects of substance use on women’s health; and epidemiologic methods. Natalie’s dissertation work aims to advance understanding of the potential impact of selection bias on study results and explores the extent to which selection bias may clarify epidemiologic paradoxes observed in the substance use literature.

Huajun Liang, M.B.B.S, Ph.D  
*University of Maryland School of Medicine*

Dr. Huajun Liang received medical and PhD degree in China. She started her postdoc training in the Neuroscience and MRI research program led by Dr. Linda Chang in 2016. Her research interests are using various neuroimaging techniques in relation to cognitive / behavioral assessments to understand brain pathophysiology associated with addiction and HIV infection.

Elisa Pabon, B.S.  
*The University of Chicago, Department of Psychiatry*

Elisa Pabon received a Bachelor of Science degree in Biological Sciences and Psychology at Carnegie Mellon University in Pittsburgh. She is now a fourth year doctoral candidate on the Committee of Neurobiology at the University of Chicago. Elisa is completing her PhD training in Dr. Harriet de Wit’s human behavioral pharmacology laboratory. Her research focuses on the physiological, subjective, and behavioral effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis. She is primarily interested in the neurobiological interactions between estrogen and exogenous cannabinoids. Her dissertation work aims to provide critical information regarding hormonal mechanisms underlying female-specific individual differences in physiological and subjective response to acute THC.

Maria A. Parker, Ph.D, M.S., M.P.H  
*Indiana University*

Dr. Maria Parker is epidemiologist trained in the areas of drug use and drug use disorders. The focus of her research is how drug use disproportionately affects vulnerable populations and opportunities for public health strategies. Dr. Parker is specifically engaged in identifying characteristics associated with opioid use at the population level and developing hypotheses that lead to more efficacious interventions and/or treatments. In addition, she also has expertise implementing tobacco regulatory science research on smokers with concurrent
affective disorders, opioid use disorder, and socioeconomic disadvantage. Dr. Parker’s strong background in epidemiology, experience with opioid related research, and familiarity with biostatistical and analytical skills allow her to make unique contributions to the field.

Anna Beth Parlier-Ahmad, M.S.
Virginia Commonwealth University

Anna Beth Parlier-Ahmad received her Bachelor of Science in Cellular and Molecular Biology from University of North Carolina at Asheville, in 2012. Subsequently, she worked as a research coordinator at Mountain Area Health Education Center in Asheville, North Carolina until 2016. Since then, she has attended Virginia Commonwealth University as a clinical psychology doctoral student in the Behavioral Medicine/Adult concentration. She earned her Master of Science from Virginia Commonwealth University in 2019. Her research interests include women’s health and substance use disorders, including perinatal substance use and mental health, sex/gender differences in substance use and addiction treatment, translation of evidence-based treatment to practice and the use of technology-based interventions.

Shannique Richards, M.A.
The City College of New York

Shannique Richards, MA is a 3rd-year doctoral student at the CCNY of the City College of New York. Her research aims to understand the mechanisms of drug addiction and other co-morbid disorders, prevention, and treatment outcomes, particularly among racial/ethnic minority women. She is interested in the impact of trauma and addiction on health outcomes, particularly, its long-term psychological sequelae. Her current research focuses on the effects of prenatal cannabis use and exposure to maternal stress on preschoolers’ neurobehavioral outcomes. Shannique aims to use mixed-method approaches to study the biopsychosocial mechanisms through which addiction and trauma interact to affect individuals’ outcomes and develop gender-responsive treatments.

Abigail Richison, M.D.
University of Arkansas for Medical Sciences

Abigail Richison, MD is a third-year psychiatry resident at the University of Arkansas for Medical Sciences (UAMS) in Little Rock, Arkansas. She graduated from Southern Methodist University (SMU) in Dallas, TX in 2009 with a Bachelor of Science in Mathematics. After graduating, she returned to her hometown of Galveston, Texas, and completed medical school at the University of Texas Medical Branch (UTMB). In 2019, she was awarded to participate in the NIDA T32 Addiction Research Training Program at UAMS and has been selected to continue to participate in this training program for the academic year of 2020-2021. Dr. Richison is currently working on research focusing on associations between cannabis use and depression in pregnant women with opioid use disorder. She is applying for an Addiction Psychiatry fellowship position in the 2021-2022 academic year with her ultimate career goals of working in an academic center surrounded by innovation and teamwork, having the opportunity to educate and mentor, and expanding her scientific curiosity through research.
Gabriella G. N. Robinson, M.A.
City University of New York

Gabriella G. N. Robinson, M.A. is a doctoral student at The Graduate Center, City University of New York, Queens College studying Clinical Neuropsychology. She earned her master’s degree at the New School with a concentration emphasis on substance abuse counseling. There she worked in the Trauma and Affective Psychophysiology Lab investigating diversity in psychophysiological data. Additionally, she worked in the TREAT lab through her Translational Research Training in Addictions for Racial/Ethnic Minorities at City College of New York and Columbia Medical Center (TRACC) training grant fellowship. Her research interests include the effects of trauma within neuropsychology, emotion regulation strategies in resilience, and culturally responsive treatments for substance use disorders.

Karl T Schmidt, Ph.D
Davidson College

Dr. Karl Schmidt is currently a postdoctoral fellow in the Psychology Department at Davidson College working with Dr. Mark Smith. As an alumnus of Davidson College, Dr. Schmidt feels fortunate to continue his training where he first discovered his research interests in understanding the neurobiological and behavioral mechanisms of drug use. Prior to his current position, Dr. Schmidt worked as a postdoctoral fellow at the University of North Carolina at Chapel Hill in the Bowles Center for Alcohol Studies in the lab of Dr. Zoe McElligott, as a graduate student in the Neuroscience Program at Emory University in the lab of Dr. David Weinshenker, and as a research technician in the Psychology Department in the lab of Dr. Linda Dykstra. In each of these positions, Dr. Schmidt has maintained a research focus on systems that influence drug effects using rodent models.

Luis E Segura, M.D., M.P.H, Dr.PH Candidate in Epidemiology
Columbia University

Luis Segura is a sixth-year doctoral candidate in the department of Epidemiology at the Columbia University Mailman School of Public Health. He completed his MD at the University Autonomous of Nuevo Leon (UANL), and his MPH at the National Institute of Public Health in Cuernavaca, Mexico. As part of Dr. Silvia S. Martin’s research team, he has worked at examining the trends over time in opioid use disorders and heroin use among youth using data from complex survey data like the National Survey on Drug Use and Health (NSDUH). He has examined the effect of cannabis legalization on opioid misuse and use disorder and has been involved in the initial descriptive data analysis of the Boricua Youth Study Gambling cohort. He is deeply interested in applying epidemiological causal inference methods in the field of substance abuse and mental health. As such, he has examined the effects of selection bias on the effect of prescription opioid misuse and cardiovascular disease.
Paige M. Shaffer, M.P.H
Division of Addiction Psychiatry, Dept. of Psychiatry, University of Massachusetts Medical School

Paige Shaffer, M.P.H. is an Instructor in Psychiatry at the University of Massachusetts Medical School Department of Psychiatry. Paige is an Epidemiologist with expertise in social and psychiatric epidemiology, and the etiology of addiction. Paige previously worked as the assistant director of Statistics and Evaluation for the Massachusetts Department of Public Health, Bureau of Substance Addiction Services (BSAS), and previously as an epidemiologist. She conducts research and writes on topics related to epidemiology, public health, homelessness, psychiatry, trauma, co-occurring disorders, disordered gambling, and addiction. She has consulted on numerous addiction-related projects with Laval University, Harvard Medical School Department of Healthcare Policy, and Harvard Medical School Division on Addiction. Much of Ms. Shaffer’s recent research has focused on the etiology and consequences of addiction. Many of these projects have focused on the implementation and evaluation of the evidence based co-occurring mental health and substance use disorders intervention model, Maintaining Independence and Sobriety through Systems Integration, Outreach, and Networking- MISSION, and MISSION-CJ. She has worked on MISSION-CJ studies in multiple settings, including prison/jail reentry settings, and specialty courts.

Jessica L. Sharp, D.Phil.
Davidson College

Dr. Jessica Sharp earned her B.A. in Psychology from Bowling Green State University (2014) and her Ph.D. in Experimental Psychology with a focus in Behavioral Neuroscience from Kent State University (2019). Dr. Sharp is dedicated to research that supports and encourages students who are passionate about STEM fields. While in graduate school, she taught a variety of undergraduate courses, was active in mentoring undergraduate students, and conducted research on how adolescent drug exposure affected serial learning and memory in male and female rodents. Currently, her work with Dr. Mark Smith assesses sex differences involved in opioid abuse.

Sara Weidberg, Ph.D
University of Oviedo

Sara Weidberg is an Assistant Professor at the University of Oviedo (Spain) since September 2019. She obtained her PhD in Psychology in 2015, with a major in the area of addictive behaviors, particularly in the behavioral assessment of impulsivity among drug dependent populations. During her research career, she has published nearly 30 research articles. She is currently working in the application of Contingency Management Techniques among smokers with other substance use disorders.
NIDA Director’s Travel Award

Samantha Auty, M.S.
Boston University School of Public Health

Samantha Auty is a doctoral student and research fellow in health services research at Boston University School of Public Health. Her research interests focus on the effects of health policy and insurance structure on service utilization, quality, and patient outcome among those with substance use disorders. Her recent work includes an assessment of the effects of the Comprehensive Addiction Recovery Act on treatment availability and utilization, and an evaluation of state-level correlates of buprenorphine waiver uptake among advance practice clinicians. Previously, she worked at the Center for Technology and Behavioral Health at Dartmouth College conducting qualitative and quantitative research investigating opioid use disorder, cannabis use disorder, and tobacco use. She received her M.S. in Healthcare Research from The Dartmouth Institute, and B.S. in Psychology and Political Science from St. Lawrence University.

Sugy Choi, M.S.
Boston University School of Public Health

Sugy Choi is a PhD candidate in the Health Services Research program at Boston University School of Public Health. She received her MS in Global Health and a BS in Foreign Service from Georgetown University. Sugy is currently an Integrated Care for Addiction, HIV and HCV Research and Education (ICAHRE) T32 Predoctoral Fellow, funded by NIDA. Her primary interests are in the field and policy level research using rigorous mixed-methods to evaluate past healthcare policies and services while improving the quality of care for the socioeconomically disadvantaged populations. She is interested in studying health services disparities among vulnerable populations such as patients with chronic comorbidities such as substance use disorders (SUD), HIV/AIDS, HCV, and severe mental health illnesses.

Danielle R. Davis, Ph.D
Yale University School of Medicine

Dr. Davis is a Postdoctoral Research Fellow in the Department of Psychiatry at Yale University’s School of Medicine under the direction of Dr. Suchitra Krishnan-Sarin and Dr. Stephanie O’Malley. Dr. Davis received her PhD from the University of Vermont in Experimental Psychology with a focus in Human Behavioral Pharmacology in 2019 under the direction of Dr. Stephen Higgins. As a graduate student, Dr. Davis’ research focused on the response of cigarette smokers with psychiatric disorders and other vulnerabilities to cigarettes with reduced nicotine content. Currently, her research is focused on examining how features of electronic cigarettes (e.g. flavors, nicotine content), as
well as population characteristics in youth and young adults contribute to the appeal and abuse liability of these products with the aim of informing regulatory and cessation efforts.

José E. Diaz, Ph.D
Columbia University Mailman School of Public Health

José E. Diaz, Ph.D., is a post-doctoral research fellow in the Substance Abuse Epidemiology Training Program at Columbia University’s Mailman School of Public Health. His research aims to advance our understanding of sexual minority health through an intersectionality framework, with an emphasis on substance use and HIV-related disparities. His current work examines sexual minority substance use disparities at the intersections of both social identities (e.g., race/ethnicity, gender) and physical locations (e.g., neighborhood environments). He received an award from the National Institutes of Health Loan Repayment Program to support this work. Dr. Diaz completed his doctorate in Sociomedical Sciences at Columbia University in 2018. His dissertation examined how varying contexts (e.g., substance use, cultural factors) were linked to HIV risk among Latinx men who have sex with men. Prior to his doctoral training, Dr. Diaz taught high school level English in Spain through a model United Nations curriculum focused on population health and inequality.

David Goodman-Meza, M.D., M.A.S
University of California Los Angeles

David Goodman-Meza, MD, MAS, is an Assistant Professor in the Division of Infectious Diseases at the David Geffen School of Medicine at UCLA. Dr. Goodman-Meza is a Mexican-American physician-scientist. He completed his medical degree with honors at Universidad Autonoma de Baja California in Tijuana, Mexico. He received his master’s degree in clinical research at UCSD and participated in a NIDA T32 post-doctoral training program at UCSD’s Division of Global Public Health mentored by Steffanie Strathdee and Thomas Patterson. He moved to New York to complete his internal medicine residency at Albert Einstein College of Medicine/Jacobi Medical Center. He completed his fellowship in Infectious Diseases at UCLA, where he was mentored by Steve Shoptaw. Dr. Goodman-Meza’s research is focused at the relationship of substance use disorders and infectious diseases, and the impact of substance use disorders treatment on infectious diseases treatment and prevention outcomes. He is currently a recipient of an NIDA K08 Career Development Award where he is training in the use of natural language processing and machine learning to evaluate outcomes of people who inject drugs who are admitted due to Staphylococcus aureus bacteremia.

Sarah Gutkind, M.S.P.H
Columbia University Mailman School of Public Health

Sarah Gutkind is a first-year pre-doctoral fellow in the Substance Abuse Epidemiology T32 Training Program at Columbia University, Mailman School of Public Health. Her research interests include harm reduction and substance use treatment outcomes for people who inject drugs (PWID). As a native Spanish speaker, she sought to expand her interests in health disparities and social determinants of health, and deepen her understanding of substance abuse epidemiology by pursuing her Masters of Science in Public Health at Johns Hopkins University. Over the last five years, she has worked with
Dr. Bruce Schackman at the Center for Health Economics of Treatment Interventions in Substance Use, Hepatitis C, and HIV (CHERISH), a NIDA-funded P30 Center of Excellence at Weill Cornell Medical College, to publish cost-effectiveness analyses alongside clinical trials for hepatitis C screening and treatment interventions in methadone maintenance treatment facilities and a cost analysis of hepatitis C linkage to care interventions for PWID and people living with HIV. Her current research under Dr. Deborah Hasin focuses on adverse outcomes associated with alcohol, cannabis, medical marijuana and the relationship with opioid use. She plans to utilize her multidisciplinary training to inform innovative research as an independent investigator in the substance use field.

**Scott E. Hadland, M.D., M.P.H, M.S.**
*Boston University School of Medicine*

Scott Hadland is pediatrician and addiction specialist at Boston Medical Center and Boston University School of Medicine. He holds triple board certification in General Pediatrics, Adolescent Medicine, and Addiction Medicine. Dr. Hadland’s clinical and research interests focus on adolescent and young adult substance use disorder prevention and treatment, and on improving care for youth and families affected by substance use. As part of these efforts, he seeks to improve education on addiction to pediatricians in the US and beyond.

Dr. Hadland has also studied the potential influence of the pharmaceutical industry in physician prescribing of opioids and stimulants. He is currently completing his second year on a K23 career development award from the National Institute on Drug Abuse (NIDA) and is a Co-Investigator on several other NIDA-funded grants, including the HEALing Communities Study.

**Lindsey R Hammerslag, Ph.D**
*University of Kentucky*

Dr. Lindsey Hammerslag earned her PhD from University of Illinois, Urbana-Champaign and currently works as a postdoctoral fellow at University of Kentucky, where she studies the neuroscience of how social and environmental factors contribute to substance use disorder. Her work maintains a focus on improving the translational validity of animal models of substance use disorder through examining understudied factors that are associated with drug use in humans, such as social environment and perceived drug value. In addition to her scientific work, she also serves as the President of the University of Kentucky Society of Postdoctoral Scholars and is passionate about enhancing scientific communication, professional development, and the postdoctoral training experience.
Asti Jackson, Ph.D  
Yale School of Medicine

Dr. Asti Jackson is an NIDA T32 postdoctoral fellow in the Department of Psychiatry (Division of Substance Abuse) at Yale School of Medicine. She received her PhD in behavioral pharmacology at Virginia Commonwealth University in 2017. During her doctoral studies, she investigated the role of nicotinic acetylcholine receptors in mouse models of nicotine dependence. She currently works as a postdoc at the Yale Center of Tobacco Regulatory Science. Her current postdoctoral research investigates adolescent and adult e-cigarette use via experimental paradigms and surveys.

Natrina "Trina" Johnson, M.S., Ph.D Candidate  
Boston University

Trina Johnson is a doctoral candidate studying health services research at Boston University School of Public Health. Her general research interests include examining and addressing disparities in healthcare access and treatment outcomes among underserved populations. Specifically, she aims to leverage qualitative and quantitative methods in both biomedical science and public health to better understand the relationship between psychiatric illness and substance use disorders. Aligned with this goal, the focus of Ms. Johnson’s dissertation is to elucidate impact of post-traumatic stress on treatment of opioid use disorder, and this work includes the development of a pre-clinical co-morbid animal model of fear and drug conditioning, quantitative analysis of health services utilization, and qualitative analysis of data she is collecting from patients and providers.

Ms. Johnson is also incorporating her training as a health services researcher in her role as a member of the Board of Directors for the Berkeley Free Clinic in California, where she has led efforts to design, implement, and analyze data from a community based evaluation survey that assesses the extent to which the services offered meets the needs of underserved and marginalized clients in the local community.

Shea M. Lemley, Ph.D  
Geisel School of Medicine at Dartmouth

Shea Lemley is a Postdoctoral Research Fellow at the Center for Technology and Behavioral Health (CTBH). Shea earned her PhD from the University of Kansas in 2018, where she primarily researched the behavioral economic underpinnings of alcohol use and risky sexual behavior. While at the University of Kansas, Shea won the 2015 Society for the Advancement of Behavior Analysis Dissertation Grant and the 2017 Outstanding Teaching and Service Award from the Department of Applied Behavioral Science. Shea is leveraging her background in behavioral economics to better understand and target self-regulatory processes in her work with Dr. Lisa Marsch. Shea is particularly interested in how technology-mediated interventions can improve measurement and promote positive behavior change.
Megan McClintick, Ph.D
University of California Los Angeles

Dr. Megan McClintick joined Dr. Edythe London’s Laboratory of Molecular Neuroimaging at UCLA in January 2017 as a Postdoctoral Fellow. Her primary research interest is focused on the use of multi-modal neuroimaging to study the neural substrates of addiction and its cognitive and behavioral correlates. Her current projects test associations between D2-type receptor availability, cognitive control, craving, and mesocorticolimbic resting state functional connectivity in individuals with stimulant use disorder. Her graduate work was completed in the laboratory of Dr. Kathleen Grant at the Oregon Health & Science University, where she examined associations between amygdalocortical resting state functional connectivity, HPA axis reactivity, temperament, and ethanol self-administration in a non-human primate model.

Tatum Oleskowicz, M.A., B.A.
University of Vermont

Tatum Oleskowicz is a first-year NIDA T32 predoctoral fellow at the University of Vermont, where she is studying clinical psychology and working with Dr. Stacey Sigmon to conduct NIH-funded clinical research evaluating novel interventions for treating opioid use disorder (OUD). Her current role consists of overseeing two ongoing large-scale, multi-site randomized clinical trials evaluating a technology-assisted Interim Buprenorphine Treatment intervention for reducing illicit opioid use, overdose risk and other adverse consequences associated with untreated OUD. Tatum is broadly interested in investigating the therapeutic promise of pharmacotherapies, behavioral economics approaches, and psychosocial interventions, in mitigating problematic opioid use and associated psychopathology. She has begun preparation of several scientific manuscripts for submission to peer-reviewed journals, and has presented her research work at the annual meetings of the Vermont Center on Behavior & Health, the American Psychological Association (APA), and the College on Problems of Drug Dependence (CPDD).

Morgan Philbin, Ph.D M.H.S
Columbia University Mailman School of Public Health

Dr. Philbin is an Assistant Professor in the Department of Sociomedical Sciences at the Columbia University Mailman School of Public Health. She conducts mixed-methods work at the intersection of social and behavioral sciences that explores the individual-, community-, and structural-level factors that influence substance use and HIV-related risks among sexual minority youth. She received the Loan Repayment Program from the National Center on Minority Health & Health Disparities for a project focused on biomedical HIV prevention and treatment among racial/ethnic and sexual minority youth. As junior faculty, her primary project (a NIDA-funded K01) examines social-structural drivers (primarily state-level policies) of substance use and HIV-related outcomes for sexual and gender minority individuals. Dr. Philbin recently served as PI of a sub-award through the Women’s Interagency HIV Study (WIHS) that included interviews with 89 women to explore their interests in, and barriers and facilitators to, the use of long-acting injectable HIV therapy (ART and PrEP). She was also Co-I on a NIDA-funded administrative supplement to explore how state-level substance use policies impact marijuana, opioid, and stimulant use among sexual minority individuals; this included an intersectional approach exploring the role of gender and race/ethnicity.
Jillian M. Rung, Ph.D  
University of Florida

Dr. Rung is a current T32 postdoctoral fellow at the University of Florida in the Substance Abuse Training Center in Public Health. She obtained her Ph.D. in experimental psychology, completing interdisciplinary training in animal and human research, with an emphasis in behavioral economic approaches and theories of addiction. She has expertise in manipulations of constructs linked to the development of addictions (e.g., impulsive decision-making). In her current position, she is learning behavioral pharmacological methodology in the pursuit of methods to reduce the abuse liability of opioids; and is assisting in the development of an adjunctive behavioral intervention for opioid use disorder. Dr. Rung is leading multiple projects applying behavioral economic theory for discovering novel ways of reducing drug use and understanding comorbidities of opioid use disorder. These training experiences and ongoing work are in the service of her goals to develop prevention methods and interventions for substance use disorders that are guided by the strength of theory and wealth of basic research.

Gregory L. Sahlem, M.D.  
Stanford University

Gregory Sahlem is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at Stanford University. He's most interested in using a neural-systems approach and brain-stimulation based treatments to develop novel treatments for Substance Use Disorders. In his virtual-poster presentation, he will present fMRI data on cue-reactivity in a cohort of participants with Cannabis Use Disorder who were entering one of two clinical trials. The data he is presenting validates a task which he and his colleagues hope to target with repetitive transcranial magnetic stimulation (rTMS).

Kristin E. Schneider, Ph.D  
Johns Hopkins Bloomberg School of Public Health

Dr. Kristin Schneider received her PhD in Public Mental Health from the Johns Hopkins Bloomberg School of Public Health, where she is currently a postdoctoral fellow. Her research focuses on overdose and HIV prevention among people who inject drugs, with an emphasis on harm reduction programming. Her work spans both rural and urban settings and is informed by local contextual factors. In particular, Dr. Schneider is interested in understanding how patterns of polysubstance use influence overdose and HIV risk and the utilization of harm reduction services. Additionally, her work also explores the mental health related sequelae of the overdose crisis among marginalized populations that experience high rates of witnessing and experiencing overdoses.
Chelsea L. Shover, Ph.D
*Stanford University*

Chelsea L. Shover, PhD is an epidemiologist and health services researcher who focuses on addiction, psychiatry, and infectious disease. She is currently a postdoctoral research fellow at Stanford University and completed her doctoral training in epidemiology at UCLA. Her research focuses on real-world implementation of efficacious pharmacotherapies (e.g., medications for opioid use disorder, HIV pre-exposure prophylaxis) and effects of policies on public health outcomes (e.g., cannabis legalization, Medicaid expansion). Dr. Shover’s article on cannabis laws and opioid overdose mortality was named one of 2019’s top 10 Proceedings of the National Academy of Sciences papers with greatest impact on public understanding of science.

Nathan D. L. Smith, ALM
*University of Florida*

Nathan Smith is a PhD student in Epidemiology at the University of Florida. He was a NIDA-funded T32 predoctoral fellow from 2017-2020, mentored by the grant PI: Dr. Linda B. Cottler. Before coming to UF he was the Program Officer at the National Center for Responsible Gaming, the largest private funder of research on gambling disorder and responsible gaming in the United States.

Tory Spindle, Ph.D
*Johns Hopkins University School of Medicine*

Dr. Tory Spindle obtained his PhD in Experimental Health Psychology from Virginia Commonwealth University. At VCU, he was part of an FDA-funded tobacco center of regulatory science (TCORS) and his research focused on the behavioral pharmacology of electronic cigarettes and other novel nicotine/tobacco products. He is currently a post-doctoral research fellow at Johns Hopkins University (JHU) School of Medicine where he conducts controlled human laboratory studies to understand the behavioral pharmacology of cannabis. He has published over 25 peer reviewed scientific journal articles, has been invited to present his work at dozens of national and international scientific conferences, and had his dissertation research funded by the National Institute on Drug Abuse (NIDA). He will soon transition to a faculty member at JHU, where he intends to establish a research program that utilizes a regulatory science framework to study cannabis in order to inform regulations and policy decisions for cannabis.
Joanna M. Streck, Ph.D Candidate  
Massachusetts General Hospital/Harvard Medical School  
Joanna Streck is a clinical psychology predoctoral intern in Behavioral Medicine at Massachusetts General Hospital/Harvard Medical School. In July, she will begin her postdoctoral fellowship in addiction funded by a K12 Career Development Award in Substance Use and Addiction Medicine. Her research interests focus on smoking cessation and harm reduction in underserved populations with an emphasis on harm reduction among individuals with opioid use disorder and other psychiatric disorders.

Justin Strickland, Ph.D  
Johns Hopkins University School of Medicine  
Justin Strickland is a postdoctoral fellow in the Behavioral Pharmacology Research Unit at the Johns Hopkins University School of Medicine. He received a Ph.D. in Experimental Psychology from the University of Kentucky (2019) and a B.S. in Biology and in Psychology from Davidson College (2014). His research focuses on the integration of human laboratory techniques and epidemiological methods to understand behavioral and pharmacological mechanisms contributing to substance use disorders. He utilizes an interdisciplinary approach by combining techniques and theoretical perspectives from the experimental analysis of behavior, neuroscience, and behavioral economics. He is particularly interested in the role that exteroceptive and interoceptive drug cues play in the development of substance use disorders and subsequent resistance to intervention.

Joji Suzuki, M.D.  
Brigham and Women’s Hospital  
Dr Suzuki is the Director of the Division of Addiction Psychiatry and Director of Addictions Education in the Department of Psychiatry, Brigham and Women’s Hospital, and an Assistant Professor of Psychiatry at Harvard Medical School (HMS). Dr Suzuki’s clinical work has focused on consultation-liaison psychiatry for both inpatients and outpatients with substance use disorders. He serves as the site director for the Addiction Psychiatry Fellowships for Partners HealthCare and Boston University School of Medicine and is very active in medical student and resident education. He is a member of Motivational Interviewing Network of Trainers and is the course director for a HMS CME course on motivational interviewing. His research is focused on integrating evidence-based addiction treatment in general medical settings, and has received funding from NIH, Brigham and Women’s Hospital, and HMS. He was recently awarded a NIDA K23 Career Development Award to receive mentored training in conducting clinical trials, and to study the impact of recovery coaches on buprenorphine treatment. He currently serves on a variety of committees, workgroups, and taskforces for Partners HealthCare, Brigham and Women’s Hospital, HMS, Massachusetts Hospital Association, and the State of Massachusetts to address the opioid epidemic.
Eric A. Thrailkill, Ph.D
University of Vermont

Dr. Thrailkill received a B.S. in Psychology from Arizona State University and a Ph.D. in Psychology from Utah State University under the supervision of Dr. Timothy Shahan. Following postdoctoral training with Dr. Mark Bouton at the University of Vermont, he accepted a faculty position in the Department of Psychological Science at the University of Vermont. Dr. Thrailkill’s research program, funded by the National Institute on Drug Abuse, uses sophisticated experimental design and theoretical approaches to connect our understanding of behavior change processes in animals to basic behavior change and decision-making mechanisms in human populations. He is interested in bidirectional translation, translation to clinical populations, harm reduction, and intervention development.

Andre B. Toussaint, M.A.
Temple University

Andre Toussaint is a Ph.D. candidate entering his 4th year in the Cognition and Neuroscience program at Temple University. He earned a Bachelor’s degree in Psychology and a Master’s degree in Biopsychology at Hunter College. As an undergraduate, Andre’s research focused on sex-differences in the molecular adaptations elicited by psychostimulant drugs such as cocaine and methamphetamine. As a Master’s student and a National Institute of General Medical Sciences (NIGMS) research trainee, Andre studied the neural circuits that underlie the cognitive impairments associated with neuropsychiatric disorders including addiction. His Master thesis work centered on identifying sex-differences in the rewarding effects of methamphetamine between two strains of adolescent mice. Since joining Dr. Wimmer’s lab at Temple University as a Ph.D. student, Andre’s work has focused on the influence of paternal opioid exposure on addiction-related behaviors in male and female progeny. Andre’s career goal is to become an independent neuroscientist at an R1 research institution where he can use his skills to investigate the neurobiology of substance abuse and related disorders. He plans to apply for the F99/K00 award in fall 2020 to facilitate his transition to a postdoctoral position.

Noel A. Vest, Ph.D
Stanford University School of Medicine

Noel A. Vest, PhD is a T32 postdoctoral research fellow in the Interdisciplinary Training Program in Pain and Substance Use Disorders in the Systems Neuroscience and Pain Lab at the Stanford. Dr. Vest is currently working with Dr. Keith Humphreys to address problems related to substance use disorder to improve public health outcomes. As a formerly incarcerated scholar, he is a strong advocate for social justice issues and public policy concerning addiction recovery and prison reentry. Dr. Vest received his Ph.D. in Experimental Psychology from Washington State University in 2019.